{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:08:54Z","timestamp":1794618534798,"version":"4.9.1"},"reference-count":470,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02843-w","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:02:26Z","timestamp":1789081346000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Insulin-like growth factor receptor signaling in physiology and disease"],"prefix":"10.1038","volume":"11","author":[{"given":"Muhammad","family":"Dilawar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoosha","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0562-1178","authenticated-orcid":false,"given":"Junguang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengxiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nenghua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8873-1227","authenticated-orcid":false,"given":"Muhammad Farrukh","family":"Nisar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6452-440X","authenticated-orcid":false,"given":"Guiqian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"2843_CR1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202401298R","volume":"38","author":"X Ruan","year":"2024","unstructured":"Ruan, X. et al. IGF signaling pathway in bone and cartilage development, homeostasis, and disease. FASEB J. 38, e70031 (2024).","journal-title":"FASEB J."},{"key":"2843_CR2","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1210\/endrev\/bnad008","volume":"44","author":"RC Baxter","year":"2023","unstructured":"Baxter, R. C. Signaling pathways of the insulin-like growth factor binding proteins. Endocr. Rev. 44, 753\u2013778 (2023).","journal-title":"Endocr. Rev."},{"key":"2843_CR3","doi-asserted-by":"publisher","first-page":"T69","DOI":"10.1530\/JME-17-0311","volume":"61","author":"F Hakuno","year":"2018","unstructured":"Hakuno, F. & Takahashi, S. I. IGF1 receptor signaling pathways. J. Mol. Endocrinol. 61, T69\u2013T86 (2018).","journal-title":"J. Mol. Endocrinol."},{"key":"2843_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/sj.emboj.7601938","volume":"27","author":"J Brown","year":"2008","unstructured":"Brown, J. et al. Structure and functional analysis of the IGF-II\/IGF2R interaction. EMBO J. 27, 265\u2013276 (2008).","journal-title":"EMBO J."},{"key":"2843_CR5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/biom11020217","volume":"11","author":"J Bailes","year":"2021","unstructured":"Bailes, J. & Soloviev, M. Insulin-like growth factor-1 (IGF-1) and its monitoring in medical diagnostic and in sports. Biomolecules 11, 217 (2021).","journal-title":"Biomolecules"},{"key":"2843_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3389\/fendo.2018.00117","volume":"9","author":"JB Allard","year":"2018","unstructured":"Allard, J. B. & Duan, C. IGF-binding proteins: why do they exist and why are there so many? Front. Endocrinol. 9, 117 (2018).","journal-title":"Front. Endocrinol."},{"key":"2843_CR7","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.15252\/emmm.201707950","volume":"9","author":"J Argente","year":"2017","unstructured":"Argente, J. et al. One level up: abnormal proteolytic regulation of IGF activity plays a role in human pathophysiology. EMBO Mol. Med. 9, 1338\u20131345 (2017).","journal-title":"EMBO Mol. Med."},{"key":"2843_CR8","doi-asserted-by":"publisher","first-page":"e36457","DOI":"10.1016\/j.heliyon.2024.e36457","volume":"10","author":"AMN Walker","year":"2024","unstructured":"Walker, A. M. N. et al. Distinct, common and synergistic effects of insulin and IGF-1 receptors on healthy murine ageing. Heliyon 10, e36457 (2024).","journal-title":"Heliyon"},{"key":"2843_CR9","doi-asserted-by":"publisher","first-page":"117862641984217","DOI":"10.1177\/1178626419842176","volume":"12","author":"MS Lewitt","year":"2019","unstructured":"Lewitt, M. S. & Boyd, G. W. The role of insulin-like growth factors and insulin-like growth factor-binding proteins in the nervous system. Biochem. Insights 12, 1178626419842176 (2019).","journal-title":"Biochem. Insights"},{"key":"2843_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ghir.2019.01.002","volume":"45","author":"Y Higashi","year":"2019","unstructured":"Higashi, Y., Gautam, S., Delafontaine, P. & Sukhanov, S. IGF-1 and cardiovascular disease. Growth Horm. IGF Res. 45, 6\u201316 (2019).","journal-title":"Growth Horm. IGF Res."},{"key":"2843_CR11","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.3390\/ijms19051308","volume":"19","author":"A Adamek","year":"2018","unstructured":"Adamek, A. & Kasprzak, A. Insulin-like growth factor (IGF) system in liver diseases. Int J. Mol. Sci. 19, 1308 (2018).","journal-title":"Int J. Mol. Sci."},{"key":"2843_CR12","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3389\/fendo.2020.00100","volume":"11","author":"C Duan","year":"2020","unstructured":"Duan, C. & Allard, J. B. Insulin-like growth factor binding protein-5 in physiology and disease. Front. Endocrinol. 11, 100 (2020).","journal-title":"Front. Endocrinol."},{"key":"2843_CR13","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1080\/13543784.2019.1694660","volume":"28","author":"H Werner","year":"2019","unstructured":"Werner, H., Sarfstein, R. & Bruchim, I. Investigational IGF1R inhibitors in early stage clinical trials for cancer therapy. Expert Opin. Investig. Drugs 28, 1101\u20131112 (2019).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2843_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2174\/157489212798357930","volume":"7","author":"ER King","year":"2012","unstructured":"King, E. R. & Wong, K. K. Insulin-like growth factor: current concepts and new developments in cancer therapy. Recent Pat. Anticancer Drug Discov. 7, 14\u201330 (2012).","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"2843_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00712-9","volume":"8","author":"C Godina","year":"2024","unstructured":"Godina, C., Pollak, M. N. & Jernstr\u00f6m, H. Targeting IGF-IR improves neoadjuvant chemotherapy efficacy in breast cancers with low IGFBP7 expression. npj Precis Oncol. 8, 212 (2024).","journal-title":"npj Precis Oncol."},{"key":"2843_CR16","doi-asserted-by":"publisher","first-page":"1571427","DOI":"10.3389\/fimmu.2025.1571427","volume":"16","author":"ACH Lee","year":"2025","unstructured":"Lee, A. C. H. & Kahaly, G. J. Targeted immunotherapies for Graves\u2019 thyroidal & orbital diseases. Front Immunol. 16, 1571427 (2025).","journal-title":"Front Immunol."},{"key":"2843_CR17","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/jnr.20081","volume":"76","author":"P Kenchappa","year":"2004","unstructured":"Kenchappa, P. et al. Rescue of TNFalpha-inhibited neuronal cells by IGF-1 involves Akt and c-Jun N-terminal kinases. J. Neurosci. Res. 76, 466\u2013474 (2004).","journal-title":"J. Neurosci. Res."},{"key":"2843_CR18","doi-asserted-by":"publisher","first-page":"39146","DOI":"10.1074\/jbc.M006964200","volume":"275","author":"S Fanayan","year":"2000","unstructured":"Fanayan, S., Firth, S. M., Butt, A. J. & Baxter, R. C. Growth inhibition by insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-beta (TGF-beta) and the type II TGF-beta receptor. J. Biol. Chem. 275, 39146\u201339151 (2000).","journal-title":"J. Biol. Chem."},{"key":"2843_CR19","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1158\/0008-5472.CAN-11-3668","volume":"72","author":"BY Liu","year":"2012","unstructured":"Liu, B. Y. et al. Mammary tumor regression elicited by Wnt signaling inhibitor requires IGFBP5. Cancer Res. 72, 1568\u20131578 (2012).","journal-title":"Cancer Res."},{"key":"2843_CR20","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.matbio.2013.09.002","volume":"35","author":"SS Skandalis","year":"2014","unstructured":"Skandalis, S. S. et al. Cross-talk between estradiol receptor and EGFR\/IGF-IR signaling pathways in estrogen-responsive breast cancers: focus on the role and impact of proteoglycans. Matrix Biol. 35, 182\u2013193 (2014).","journal-title":"Matrix Biol."},{"key":"2843_CR21","first-page":"825","volume":"49","author":"WD Salmon Jr.","year":"1957","unstructured":"Salmon, W. D. Jr. & Daughaday, W. H. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J. Lab Clin. Med. 49, 825\u2013836 (1957).","journal-title":"J. Lab Clin. Med."},{"key":"2843_CR22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/235107a0","volume":"235","author":"WH Daughaday","year":"1972","unstructured":"Daughaday, W. H. et al. Somatomedin: proposed designation for sulphation factor. Nature 235, 107\u2013107 (1972).","journal-title":"Nature"},{"key":"2843_CR23","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1073\/pnas.73.7.2365","volume":"73","author":"E Rinderknecht","year":"1976","unstructured":"Rinderknecht, E. & Humbel, R. E. Polypeptides with nonsuppressible insulin-like and cell-growth promoting activities in human serum: isolation, chemical characterization, and some biological properties of forms I and II. Proc. Natl. Acad. Sci. USA 73, 2365\u20132369 (1976).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2843_CR24","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1159\/000527123","volume":"95","author":"BS Miller","year":"2022","unstructured":"Miller, B. S., Rogol, A. D. & Rosenfeld, R. G. The history of the insulin-like growth factor system. Horm. Res. Paediatr. 95, 619\u2013630 (2022).","journal-title":"Horm. Res. Paediatr."},{"key":"2843_CR25","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1210\/jcem-71-4-806","volume":"71","author":"LC Giudice","year":"1990","unstructured":"Giudice, L. C. et al. Insulin-like growth factor binding proteins in maternal serum throughout gestation and in the puerperium: effects of a pregnancy-associated serum protease activity. J. Clin. Endocrinol. Metab. 71, 806\u2013816 (1990).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2843_CR26","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/0003-2697(86)90507-5","volume":"154","author":"P Hossenlopp","year":"1986","unstructured":"Hossenlopp, P. et al. Analysis of serum insulin-like growth factor binding proteins using western blotting: use of the method for titration of the binding proteins and competitive binding studies. Anal. Biochem. 154, 138\u2013143 (1986).","journal-title":"Anal. Biochem."},{"key":"2843_CR27","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1002\/j.1460-2075.1986.tb04528.x","volume":"5","author":"A Ullrich","year":"1986","unstructured":"Ullrich, A. et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 5, 2503\u20132512 (1986).","journal-title":"EMBO J."},{"key":"2843_CR28","doi-asserted-by":"publisher","first-page":"11843","DOI":"10.1016\/S0021-9258(18)80143-0","volume":"264","author":"RC Baxter","year":"1989","unstructured":"Baxter, R. C., Martin, J. L. & Beniac, V. A. High molecular weight insulin-like growth factor binding protein complex. Purification and properties of the acid-labile subunit from human serum. J. Biol. Chem. 264, 11843\u201311848 (1989).","journal-title":"J. Biol. Chem."},{"key":"2843_CR29","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1210\/jcem-70-5-1347","volume":"70","author":"RC Baxter","year":"1990","unstructured":"Baxter, R. C. Circulating levels and molecular distribution of the acid-labile (alpha) subunit of the high molecular weight insulin-like growth factor-binding protein complex. J. Clin. Endocrinol. Metab. 70, 1347\u20131353 (1990).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2843_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1210\/edrv-16-2-143","volume":"16","author":"D LeRoith","year":"1995","unstructured":"LeRoith, D., Werner, H., Beitner-Johnson, D. & Roberts, C. T. Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr. Rev. 16, 143\u2013163 (1995).","journal-title":"Endocr. Rev."},{"key":"2843_CR31","first-page":"4848","volume":"54","author":"M Resnicoff","year":"1994","unstructured":"Resnicoff, M. et al. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res. 54, 4848\u20134850 (1994).","journal-title":"Cancer Res."},{"key":"2843_CR32","first-page":"1761","volume":"56","author":"MA Steller","year":"1996","unstructured":"Steller, M. A. et al. Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res. 56, 1761\u20131765 (1996).","journal-title":"Cancer Res."},{"key":"2843_CR33","doi-asserted-by":"publisher","first-page":"5834","DOI":"10.1158\/1078-0432.CCR-07-1118","volume":"13","author":"P Haluska","year":"2007","unstructured":"Haluska, P. et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin. Cancer Res. 13, 5834\u20135840 (2007).","journal-title":"Clin. Cancer Res."},{"key":"2843_CR34","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1158\/1535-7163.MCT-08-0265","volume":"7","author":"J Rodon","year":"2008","unstructured":"Rodon, J., DeSantos, V., Ferry, R. J. Jr. & Kurzrock, R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol. Cancer Ther. 7, 2575\u20132588 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"2843_CR35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.molmet.2018.01.013","volume":"9","author":"S Logan","year":"2018","unstructured":"Logan, S. et al. Insulin-like growth factor receptor signaling regulates working memory, mitochondrial metabolism, and amyloid-\u03b2 uptake in astrocytes. Mol. Metab. 9, 141\u2013155 (2018).","journal-title":"Mol. Metab."},{"key":"2843_CR36","doi-asserted-by":"publisher","first-page":"6817","DOI":"10.3390\/ijms22136817","volume":"22","author":"T Okuyama","year":"2021","unstructured":"Okuyama, T., Kyohara, M., Terauchi, Y. & Shirakawa, J. The roles of the IGF axis in the regulation of the metabolism: interaction and difference between insulin receptor signaling and IGF-I receptor signaling. Int. J. Mol. Sci. 22, 6817 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2843_CR37","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas, R. S. et al. Teprotumumab for the treatment of active thyroid eye disease. N. Engl. J. Med. 382, 341\u2013352 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2843_CR38","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1158\/1535-7163.MCT-08-1171","volume":"8","author":"PJ Beltran","year":"2009","unstructured":"Beltran, P. J. et al. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol. Cancer Ther. 8, 1095\u20131105 (2009).","journal-title":"Mol. Cancer Ther."},{"key":"2843_CR39","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1158\/1078-0432.CCR-13-3448","volume":"20","author":"PJ Beltran","year":"2014","unstructured":"Beltran, P. J. et al. Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy. Clin. Cancer Res. 20, 2947\u20132958 (2014).","journal-title":"Clin. Cancer Res."},{"key":"2843_CR40","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s11523-017-0514-5","volume":"12","author":"A Simpson","year":"2017","unstructured":"Simpson, A. et al. Insulin-like growth factor (IGF) pathway targeting in cancer: role of the IGF axis and opportunities for future combination studies. Target Oncol. 12, 571\u2013597 (2017).","journal-title":"Target Oncol."},{"key":"2843_CR41","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.2741\/2925","volume":"13","author":"AJ Casa","year":"2008","unstructured":"Casa, A. J. et al. The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front Biosci. 13, 3273\u20133287 (2008).","journal-title":"Front Biosci."},{"key":"2843_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41862-x","volume":"14","author":"CM Viola","year":"2023","unstructured":"Viola, C. M. et al. Structural conservation of insulin\/IGF signalling axis at the insulin receptors level in Drosophila and humans. Nat. Commun. 14, 6271 (2023).","journal-title":"Nat. Commun."},{"key":"2843_CR43","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/cen.12446","volume":"80","author":"C Livingstone","year":"2014","unstructured":"Livingstone, C. & Borai, A. Insulin-like growth factor-II: its role in metabolic and endocrine disease. Clin. Endocrinol. 80, 773\u2013781 (2014).","journal-title":"Clin. Endocrinol."},{"key":"2843_CR44","doi-asserted-by":"publisher","first-page":"5590","DOI":"10.1002\/j.1460-2075.1994.tb06896.x","volume":"13","author":"H Terasawa","year":"1994","unstructured":"Terasawa, H. et al. Solution structure of human insulin-like growth factor II; recognition sites for receptors and binding proteins. EMBO J. 13, 5590\u20135597 (1994).","journal-title":"EMBO J."},{"key":"2843_CR45","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/s42003-023-05239-6","volume":"6","author":"P Potalitsyn","year":"2023","unstructured":"Potalitsyn, P. et al. Non-glycosylated IGF2 prohormones are more mitogenic than native IGF2. Commun. Biol. 6, 863 (2023).","journal-title":"Commun. Biol."},{"key":"2843_CR46","unstructured":"Shimizu, M. in Handbook of Hormones (Second Edition) (eds Hironori Ando, Kazuyoshi Ukena, & Shinji Nagata) 289-292 (Academic Press, 2021)."},{"key":"2843_CR47","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.bcp.2010.06.013","volume":"80","author":"SA Rosenzweig","year":"2010","unstructured":"Rosenzweig, S. A. & Atreya, H. S. Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem. Pharmacol. 80, 1115\u20131124 (2010).","journal-title":"Biochem. Pharmacol."},{"key":"2843_CR48","doi-asserted-by":"crossref","unstructured":"Yee, D. in Cancer Therapeutic Targets (ed John L. Marshall) 739-743 (Springer New York, 2017).","DOI":"10.1007\/978-1-4419-0717-2_4"},{"key":"2843_CR49","doi-asserted-by":"publisher","first-page":"101245","DOI":"10.1016\/j.molmet.2021.101245","volume":"52","author":"D LeRoith","year":"2021","unstructured":"LeRoith, D., Holly, J. M. P. & Forbes, B. E. Insulin-like growth factors: Ligands, binding proteins, and receptors. Mol. Metab. 52, 101245 (2021).","journal-title":"Mol. Metab."},{"key":"2843_CR50","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3389\/fendo.2012.00038","volume":"3","author":"BE Forbes","year":"2012","unstructured":"Forbes, B. E., McCarthy, P. & Norton, R. S. Insulin-like growth factor binding proteins: a structural perspective. Front. Endocrinol. 3, 38 (2012).","journal-title":"Front. Endocrinol."},{"key":"2843_CR51","first-page":"800","volume":"10","author":"B Hosnedlova","year":"2020","unstructured":"Hosnedlova, B. et al. Associations between IGF1, IGFBP2 and TGF\u00df3 genes polymorphisms and growth performance of broiler chicken lines. Anim Open Access J. MDPI. 10, 800 (2020).","journal-title":"Anim Open Access J. MDPI."},{"key":"2843_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.aqrep.2024.101971","volume":"35","author":"X Yao","year":"2024","unstructured":"Yao, X. et al. Genome-wide identification of igfbp genes and their different growth expression patterns of mandarin fish. Aquac. Rep. 35, 101971 (2024).","journal-title":"Aquac. Rep."},{"key":"2843_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.psj.2024.104416","volume":"103","author":"W Zhang","year":"2024","unstructured":"Zhang, W. et al. IGF2\/IGFBP4 reduces apoptosis and increases free cholesterol of chicken granulosa cells in vitro. Poult. Sci. 103, 104416 (2024).","journal-title":"Poult. Sci."},{"key":"2843_CR54","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1210\/en.2011-0047","volume":"152","author":"DO Daza","year":"2011","unstructured":"Daza, D. O. et al. Evolution of the insulin-like growth factor binding protein (IGFBP) family. Endocrinology 152, 2278\u20132289 (2011).","journal-title":"Endocrinology"},{"key":"2843_CR55","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1182\/bloodadvances.2020003627","volume":"5","author":"LL Artico","year":"2021","unstructured":"Artico, L. L. et al. Physiologic IGFBP7 levels prolong IGF1R activation in acute lymphoblastic leukemia. Blood Adv. 5, 3633\u20133646 (2021).","journal-title":"Blood Adv."},{"key":"2843_CR56","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1043-2760(03)00049-3","volume":"14","author":"RC Bunn","year":"2003","unstructured":"Bunn, R. C. & Fowlkes, J. L. Insulin-like growth factor binding protein proteolysis. Trends Endocrinol. Metab. TEM. 14, 176\u2013181 (2003).","journal-title":"Trends Endocrinol. Metab. TEM."},{"key":"2843_CR57","doi-asserted-by":"publisher","first-page":"13028","DOI":"10.1073\/pnas.0605652103","volume":"103","author":"T Sitar","year":"2006","unstructured":"Sitar, T. et al. Structural basis for the inhibition of insulin-like growth factors by insulin-like growth factor-binding proteins. Proc. Natl. Acad. Sci. USA 103, 13028\u201313033 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2843_CR58","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41574-024-00970-4","volume":"20","author":"RC Baxter","year":"2024","unstructured":"Baxter, R. C. Endocrine and cellular physiology and pathology of the insulin-like growth factor acid-labile subunit. Nat. Rev. Endocrinol. 20, 414\u2013425 (2024).","journal-title":"Nat. Rev. Endocrinol."},{"key":"2843_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32214-2","volume":"13","author":"H Kim","year":"2022","unstructured":"Kim, H. et al. Structural basis for assembly and disassembly of the IGF\/IGFBP\/ALS ternary complex. Nat. Commun. 13, 4434 (2022).","journal-title":"Nat. Commun."},{"key":"2843_CR60","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s12325-020-01581-x","volume":"38","author":"F Song","year":"2021","unstructured":"Song, F. et al. The roles of insulin-like growth factor binding protein family in development and diseases. Adv. Ther. 38, 885\u2013903 (2021).","journal-title":"Adv. Ther."},{"key":"2843_CR61","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.bbrc.2016.08.059","volume":"478","author":"Y Ma","year":"2016","unstructured":"Ma, Y. et al. Insulin-like growth factor-binding protein-3 inhibits IGF-1-induced proliferation of human hepatocellular carcinoma cells by controlling bFGF and PDGF autocrine\/paracrine loops. Biochem. Biophys. Res. Commun. 478, 964\u2013969 (2016).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2843_CR62","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1038\/onc.2012.264","volume":"32","author":"S Grkovic","year":"2013","unstructured":"Grkovic, S. et al. IGFBP-3 binds GRP78, stimulates autophagy and promotes the survival of breast cancer cells exposed to adverse microenvironments. Oncogene 32, 2412\u20132420 (2013).","journal-title":"Oncogene"},{"key":"2843_CR63","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.gene.2015.06.028","volume":"569","author":"RC Baxter","year":"2015","unstructured":"Baxter, R. C. Nuclear actions of insulin-like growth factor binding protein-3. Gene 569, 7\u201313 (2015).","journal-title":"Gene"},{"key":"2843_CR64","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3389\/fendo.2018.00120","volume":"9","author":"SM Julovi","year":"2018","unstructured":"Julovi, S. M., Martin, J. L. & Baxter, R. C. Nuclear insulin-like growth factor binding protein-3 as a biomarker in triple-negative breast cancer xenograft tumors: effect of targeted therapy and comparison with chemotherapy. Front. Endocrinol. 9, 120 (2018).","journal-title":"Front. Endocrinol."},{"key":"2843_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28360-2","volume":"13","author":"F D\u2019Addio","year":"2022","unstructured":"D\u2019Addio, F. et al. The IGFBP3\/TMEM219 pathway regulates beta cell homeostasis. Nat. Commun. 13, 684 (2022).","journal-title":"Nat. Commun."},{"key":"2843_CR66","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1128\/MCB.19.5.3278","volume":"19","author":"F Frasca","year":"1999","unstructured":"Frasca, F. et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol. Cell Biol. 19, 3278\u20133288 (1999).","journal-title":"Mol. Cell Biol."},{"key":"2843_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03219-7","volume":"9","author":"Y Xu","year":"2018","unstructured":"Xu, Y. et al. How ligand binds to the type 1 insulin-like growth factor receptor. Nat. Commun. 9, 821 (2018).","journal-title":"Nat. Commun."},{"key":"2843_CR68","doi-asserted-by":"publisher","first-page":"11004","DOI":"10.1016\/S0021-9258(18)60418-1","volume":"264","author":"ML Bayne","year":"1989","unstructured":"Bayne, M. L. et al. The C region of human insulin-like growth factor (IGF) I is required for high affinity binding to the type 1 IGF receptor. J. Biol. Chem. 264, 11004\u201311008 (1989).","journal-title":"J. Biol. Chem."},{"key":"2843_CR69","doi-asserted-by":"publisher","first-page":"7656","DOI":"10.1074\/jbc.M808061200","volume":"284","author":"CL Alvino","year":"2009","unstructured":"Alvino, C. L. et al. A novel approach to identify two distinct receptor binding surfaces of insulin-like growth factor II. J. Biol. Chem. 284, 7656\u20137664 (2009).","journal-title":"J. Biol. Chem."},{"key":"2843_CR70","doi-asserted-by":"publisher","first-page":"20821","DOI":"10.1074\/jbc.M802620200","volume":"283","author":"L Gauguin","year":"2008","unstructured":"Gauguin, L. et al. Alanine scanning of a putative receptor binding surface of insulin-like growth factor-I. J. Biol. Chem. 283, 20821\u201320829 (2008).","journal-title":"J. Biol. Chem."},{"key":"2843_CR71","doi-asserted-by":"publisher","first-page":"25869","DOI":"10.1074\/jbc.M605189200","volume":"281","author":"R Slaaby","year":"2006","unstructured":"Slaaby, R. et al. Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant. J. Biol. Chem. 281, 25869\u201325874 (2006).","journal-title":"J. Biol. Chem."},{"key":"2843_CR72","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1042\/BJ20061709","volume":"403","author":"S Benyoucef","year":"2007","unstructured":"Benyoucef, S., Surinya, K. H., Hadaschik, D. & Siddle, K. Characterization of insulin\/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation. Biochem. J. 403, 603\u2013613 (2007).","journal-title":"Biochem. J."},{"key":"2843_CR73","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1432-1033.1992.tb17183.x","volume":"208","author":"A Domeyne","year":"1992","unstructured":"Domeyne, A. et al. Preferential binding of insulin-like growth factor-II (IGF-II) to a putative alpha 2 beta 2 IGF-II receptor type in C2 myoblasts. Eur. J. Biochem. 208, 273\u2013279 (1992).","journal-title":"Eur. J. Biochem."},{"key":"2843_CR74","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s12672-021-00407-8","volume":"12","author":"JV Mills","year":"2021","unstructured":"Mills, J. V. et al. IGF-1R nuclear import and recruitment to chromatin involves both alpha and beta subunits. Discov. Oncol. 12, 13 (2021).","journal-title":"Discov. Oncol."},{"key":"2843_CR75","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd917","volume":"1","author":"P De Meyts","year":"2002","unstructured":"De Meyts, P. & Whittaker, J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat. Rev. Drug Discov. 1, 769\u2013783 (2002).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2843_CR76","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.03772","volume":"3","author":"JM Kavran","year":"2014","unstructured":"Kavran, J. M. et al. How IGF-1 activates its receptor. eLife 3, e03772 (2014).","journal-title":"eLife"},{"key":"2843_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.108021","volume":"301","author":"N McDermott","year":"2025","unstructured":"McDermott, N. et al. \u03b2(1)-integrin controls IGF-1R internalization and intracellular signaling. J. Biol. Chem. 301, 108021 (2025).","journal-title":"J. Biol. Chem."},{"key":"2843_CR78","doi-asserted-by":"publisher","first-page":"620013","DOI":"10.3389\/fendo.2020.620013","volume":"11","author":"L Rieger","year":"2020","unstructured":"Rieger, L. & O\u2019Connor, R. Controlled signaling-insulin-like growth factor receptor endocytosis and presence at intracellular compartments. Front. Endocrinol. 11, 620013 (2020).","journal-title":"Front. Endocrinol."},{"key":"2843_CR79","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1038\/onc.2014.165","volume":"34","author":"S Packham","year":"2015","unstructured":"Packham, S. et al. Nuclear translocation of IGF-1R via p150(Glued) and an importin-\u03b2\/RanBP2-dependent pathway in cancer cells. Oncogene 34, 2227\u20132238 (2015).","journal-title":"Oncogene"},{"key":"2843_CR80","doi-asserted-by":"publisher","first-page":"108307","DOI":"10.1016\/j.mrrev.2020.108307","volume":"784","author":"E Poreba","year":"2020","unstructured":"Poreba, E. & Durzynska, J. Nuclear localization and actions of the insulin-like growth factor 1 (IGF-1) system components: transcriptional regulation and DNA damage response. Mutat. Res. Rev. Mutat. Res. 784, 108307 (2020).","journal-title":"Mutat. Res. Rev. Mutat. Res."},{"key":"2843_CR81","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1158\/0008-5472.CAN-17-3498","volume":"78","author":"T Aleksic","year":"2018","unstructured":"Aleksic, T. et al. Nuclear IGF1R interacts with regulatory regions of chromatin to promote RNA polymerase II recruitment and gene expression associated with advanced tumor stage. Cancer Res. 78, 3497\u20133509 (2018).","journal-title":"Cancer Res."},{"key":"2843_CR82","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41580-025-00826-3","volume":"26","author":"E Choi","year":"2025","unstructured":"Choi, E., Duan, C. & Bai, X. C. Regulation and function of insulin and insulin-like growth factor receptor signalling. Nat. Rev. Mol. Cell Biol. 26, 558\u2013580 (2025).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2843_CR83","doi-asserted-by":"crossref","unstructured":"Sarfstein, R. & Werner, H. in Receptor Tyrosine Kinases: Family and Subfamilies (eds Deric L. W. & Yosef, Y.) 297\u2013320 (Springer International Publishing, 2015).","DOI":"10.1007\/978-3-319-11888-8_7"},{"key":"2843_CR84","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3390\/genes10120984","volume":"10","author":"S Payankaulam","year":"2019","unstructured":"Payankaulam, S., Raicu, A. M. & Arnosti, D. N. Transcriptional regulation of INSR, the insulin receptor gene. Genes 10, 984 (2019).","journal-title":"Genes"},{"key":"2843_CR85","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41392-022-01073-0","volume":"7","author":"M Li","year":"2022","unstructured":"Li, M. et al. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduct. Target Ther. 7, 216 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"2843_CR86","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.str.2022.05.007","volume":"30","author":"Y Xu","year":"2022","unstructured":"Xu, Y. et al. How insulin-like growth factor I binds to a hybrid insulin receptor type 1 insulin-like growth factor receptor. Structure 30, 1098\u20131108. e1096 (2022).","journal-title":"Structure"},{"key":"2843_CR87","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1007\/s12035-016-9849-7","volume":"54","author":"Y Wang","year":"2017","unstructured":"Wang, Y., MacDonald, R. G., Thinakaran, G. & Kar, S. Insulin-like growth factor-II\/cation-independent mannose 6-phosphate receptor in neurodegenerative diseases. Mol. Neurobiol. 54, 2636\u20132658 (2017).","journal-title":"Mol. Neurobiol."},{"key":"2843_CR88","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.str.2020.08.002","volume":"28","author":"AJ Bochel","year":"2020","unstructured":"Bochel, A. J. et al. Structure of the human cation-independent mannose 6-phosphate\/IGF2 receptor domains 7-11 uncovers the mannose 6-phosphate binding site of domain 9. Structure 28, 1300\u20131312.e1305 (2020).","journal-title":"Structure"},{"key":"2843_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2020.101343","volume":"55","author":"N Bano","year":"2020","unstructured":"Bano, N. et al. Analyzing structural differences between insulin receptor (IR) and IGF1R for designing small molecule allosteric inhibitors of IGF1R as novel anti-cancer agents. Growth Horm. IGF Res. 55, 101343 (2020).","journal-title":"Growth Horm. IGF Res."},{"key":"2843_CR90","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz1466","volume":"6","author":"R Wang","year":"2020","unstructured":"Wang, R. et al. Marked structural rearrangement of mannose 6-phosphate\/IGF2 receptor at different pH environments. Sci. Adv. 6, eaaz1466 (2020).","journal-title":"Sci. Adv."},{"key":"2843_CR91","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S0083-6729(08)00625-0","volume":"80","author":"J Brown","year":"2009","unstructured":"Brown, J., Jones, E. Y. & Forbes, B. E. Interactions of IGF-II with the IGF2R\/cation-independent mannose-6-phosphate receptor mechanism and biological outcomes. Vitam. Horm. 80, 699\u2013719 (2009).","journal-title":"Vitam. Horm."},{"key":"2843_CR92","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.imlet.2017.08.011","volume":"190","author":"V Leksa","year":"2017","unstructured":"Leksa, V., Ilkov\u00e1, A., Vi\u010d\u00edkov\u00e1, K. & Stockinger, H. Unravelling novel functions of the endosomal transporter mannose 6-phosphate\/insulin-like growth factor receptor (CD222) in health and disease: an emerging regulator of the immune system. Immunol. Lett. 190, 194\u2013200 (2017).","journal-title":"Immunol. Lett."},{"key":"2843_CR93","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911019","volume":"12","author":"P Bella","year":"2020","unstructured":"Bella, P. et al. Blockade of IGF2R improves muscle regeneration and ameliorates Duchenne muscular dystrophy. EMBO Mol. Med. 12, e11019 (2020).","journal-title":"EMBO Mol. Med."},{"key":"2843_CR94","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41421-022-00426-x","volume":"8","author":"XK Gao","year":"2022","unstructured":"Gao, X. K. et al. Phase separation of insulin receptor substrate 1 drives the formation of insulin\/IGF-1 signalosomes. Cell Discov. 8, 60 (2022).","journal-title":"Cell Discov."},{"key":"2843_CR95","doi-asserted-by":"publisher","first-page":"a008946","DOI":"10.1101\/cshperspect.a008946","volume":"5","author":"SR Hubbard","year":"2013","unstructured":"Hubbard, S. R. The insulin receptor: both a prototypical and atypical receptor tyrosine kinase. Cold Spring Harb. Perspect. Biol. 5, a008946 (2013).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2843_CR96","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev-biochem-052521-033250","volume":"92","author":"E Choi","year":"2023","unstructured":"Choi, E. & Bai, X. C. The activation mechanism of the insulin receptor: a structural perspective. Annu. Rev. Biochem. 92, 247\u2013272 (2023).","journal-title":"Annu. Rev. Biochem."},{"key":"2843_CR97","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.32893","volume":"7","author":"Y Yoneyama","year":"2018","unstructured":"Yoneyama, Y. et al. IRS-1 acts as an endocytic regulator of IGF-I receptor to facilitate sustained IGF signaling. eLife 7, e32893 (2018).","journal-title":"eLife"},{"key":"2843_CR98","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1172\/JCI7917","volume":"105","author":"Y Kido","year":"2000","unstructured":"Kido, Y. et al. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J. Clin. Investig. 105, 199\u2013205 (2000).","journal-title":"J. Clin. Investig."},{"key":"2843_CR99","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.4161\/cc.10.11.15824","volume":"10","author":"LM Shaw","year":"2011","unstructured":"Shaw, L. M. The insulin receptor substrate (IRS) proteins: at the intersection of metabolism and cancer. Cell Cycle 10, 1750\u20131756 (2011).","journal-title":"Cell Cycle"},{"key":"2843_CR100","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.bbrc.2023.09.036","volume":"680","author":"M Ahmed","year":"2023","unstructured":"Ahmed, M., Biswas, T. & Mondal, S. The strategic involvement of IRS in cancer progression. Biochem. Biophys. Res. Commun. 680, 141\u2013160 (2023).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2843_CR101","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/B978-0-12-407766-9.00009-2","volume":"91","author":"SC Ranieri","year":"2013","unstructured":"Ranieri, S. C., Fusco, S. & Pani, G. p66(ShcA): linking mammalian longevity with obesity-induced insulin resistance. Vitam. Horm. 91, 219\u2013241 (2013).","journal-title":"Vitam. Horm."},{"key":"2843_CR102","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3109\/13813455.2011.562513","volume":"117","author":"A Natalicchio","year":"2011","unstructured":"Natalicchio, A. et al. p66Shc, a multifaceted protein linking Erk signalling, glucose metabolism, and oxidative stress. Arch. Physiol. Biochem. 117, 116\u2013124 (2011).","journal-title":"Arch. Physiol. Biochem."},{"key":"2843_CR103","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.3390\/ijms25073656","volume":"25","author":"CP-LAC da","year":"2024","unstructured":"da, C. P.-L. A. C., Melia, E. & Hays, F. A. Exploring the gut-mitochondrial axis: p66Shc adapter protein and its implications for metabolic disorders. Int. J. Mol. Sci. 25, 3656 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2843_CR104","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1128\/MCB.17.4.1824","volume":"17","author":"N Gotoh","year":"1997","unstructured":"Gotoh, N., Toyoda, M. & Shibuya, M. Tyrosine phosphorylation sites at amino acids 239 and 240 of Shc are involved in epidermal growth factor-induced mitogenic signaling that is distinct from Ras\/mitogen-activated protein kinase activation. Mol. Cell Biol. 17, 1824\u20131831 (1997).","journal-title":"Mol. Cell Biol."},{"key":"2843_CR105","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.1074\/jbc.273.8.4672","volume":"273","author":"JC Chow","year":"1998","unstructured":"Chow, J. C., Condorelli, G. & Smith, R. J. Insulin-like growth factor-I receptor internalization regulates signaling via the Shc\/mitogen-activated protein kinase pathway, but not the insulin receptor substrate-1 pathway. J. Biol. Chem. 273, 4672\u20134680 (1998).","journal-title":"J. Biol. Chem."},{"key":"2843_CR106","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","volume":"296","author":"LC Cantley","year":"2002","unstructured":"Cantley, L. C. The phosphoinositide 3-kinase pathway. Science 296, 1655\u20131657 (2002).","journal-title":"Science"},{"key":"2843_CR107","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","volume":"169","author":"BD Manning","year":"2017","unstructured":"Manning, B. D. & Toker, A. AKT\/PKB signaling: navigating the network. Cell 169, 381\u2013405 (2017).","journal-title":"Cell"},{"key":"2843_CR108","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1126\/science.1106148","volume":"307","author":"DD Sarbassov","year":"2005","unstructured":"Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex. Science 307, 1098\u20131101 (2005).","journal-title":"Science"},{"key":"2843_CR109","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante, M. & Sabatini, D. M. mTOR signaling in growth control and disease. Cell 149, 274\u2013293 (2012).","journal-title":"Cell"},{"key":"2843_CR110","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrm3351","volume":"13","author":"D Leto","year":"2012","unstructured":"Leto, D. & Saltiel, A. R. Regulation of glucose transport by insulin: traffic control of GLUT4. Nat. Rev. Mol. Cell Biol. 13, 383\u2013396 (2012).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2843_CR111","doi-asserted-by":"crossref","unstructured":"Cormerais, Y. et al. AKT-mediated phosphorylation of TSC2 controls stimulus- and tissue-specific mTORC1 signaling and organ growth. Dev Cell 60, 2544\u20132557.e7 (2025).","DOI":"10.1016\/j.devcel.2025.05.008"},{"key":"2843_CR112","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.7150\/ijbs.27173","volume":"14","author":"X Huang","year":"2018","unstructured":"Huang, X., Liu, G., Guo, J. & Su, Z. The PI3K\/AKT pathway in obesity and type 2 diabetes. Int. J. Biol. Sci. 14, 1483\u20131496 (2018).","journal-title":"Int. J. Biol. Sci."},{"key":"2843_CR113","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He, Y. et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct. Target Ther. 6, 425 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"2843_CR114","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41556-018-0169-1","volume":"20","author":"RJ Nichols","year":"2018","unstructured":"Nichols, R. J. et al. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nat. Cell Biol. 20, 1064\u20131073 (2018).","journal-title":"Nat. Cell Biol."},{"key":"2843_CR115","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.bbadis.2009.12.009","volume":"1802","author":"EK Kim","year":"2010","unstructured":"Kim, E. K. & Choi, E. J. Pathological roles of MAPK signaling pathways in human diseases. Biochim. Biophys. Acta 1802, 396\u2013405 (2010).","journal-title":"Biochim. Biophys. Acta"},{"key":"2843_CR116","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nrendo.2018.22","volume":"14","author":"MB Ranke","year":"2018","unstructured":"Ranke, M. B. & Wit, J. M. Growth hormone - past, present and future. Nat. Rev. Endocrinol. 14, 285\u2013300 (2018).","journal-title":"Nat. Rev. Endocrinol."},{"key":"2843_CR117","doi-asserted-by":"publisher","first-page":"10955","DOI":"10.1074\/jbc.M412808200","volume":"280","author":"Y Wang","year":"2005","unstructured":"Wang, Y. & Jiang, H. Identification of a distal STAT5-binding DNA region that may mediate growth hormone regulation of insulin-like growth factor-I gene expression. J. Biol. Chem. 280, 10955\u201310963 (2005).","journal-title":"J. Biol. Chem."},{"key":"2843_CR118","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.3390\/nu5104184","volume":"5","author":"M Maggio","year":"2013","unstructured":"Maggio, M. et al. IGF-1, the cross road of the nutritional, inflammatory and hormonal pathways to frailty. Nutrients 5, 4184\u20134205 (2013).","journal-title":"Nutrients"},{"key":"2843_CR119","first-page":"61","volume":"16","author":"CN Gulick","year":"2020","unstructured":"Gulick, C. N. et al. Exercise, dietary protein, and combined effect on IGF-1. Int J. Sci. Res Methodol. 16, 61\u201377 (2020).","journal-title":"Int J. Sci. Res Methodol."},{"key":"2843_CR120","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1590\/1980-57642018dn12-020003","volume":"12","author":"AM Stein","year":"2018","unstructured":"Stein, A. M. et al. Physical exercise, IGF-1 and cognition A systematic review of experimental studies in the elderly. Dement. Neuropsychol. 12, 114\u2013122 (2018).","journal-title":"Dement. Neuropsychol."},{"key":"2843_CR121","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13195-023-01288-5","volume":"15","author":"Z Cao","year":"2023","unstructured":"Cao, Z. et al. Circulating insulin-like growth factor-1 and brain health: evidence from 369,711 participants in the UK Biobank. Alzheimers Res. Ther. 15, 140 (2023).","journal-title":"Alzheimers Res. Ther."},{"key":"2843_CR122","doi-asserted-by":"crossref","first-page":"pt9","DOI":"10.1126\/scisignal.2003484","volume":"5","author":"L S\u00e4vendahl","year":"2012","unstructured":"S\u00e4vendahl, L. The effect of acute and chronic stress on growth. Sci. Signal 5, pt9 (2012).","journal-title":"Sci. Signal"},{"key":"2843_CR123","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1229165","volume":"17","author":"Y He","year":"2023","unstructured":"He, Y. et al. The role of IGF-1 in exercise to improve obesity-related cognitive dysfunction. Front. Neurosci. 17, 1229165 (2023).","journal-title":"Front. Neurosci."},{"key":"2843_CR124","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.7150\/ijbs.31999","volume":"15","author":"X Zheng","year":"2019","unstructured":"Zheng, X., Lu, G., Yao, Y. & Gu, W. An autocrine IL-6\/IGF-1R loop mediates EMT and promotes tumor growth in non-small cell lung cancer. Int. J. Biol. Sci. 15, 1882\u20131891 (2019).","journal-title":"Int. J. Biol. Sci."},{"key":"2843_CR125","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/pr.2014.84","volume":"76","author":"D Choukair","year":"2014","unstructured":"Choukair, D. et al. Inhibition of IGF-I-related intracellular signaling pathways by proinflammatory cytokines in growth plate chondrocytes. Pediatr. Res 76, 245\u2013251 (2014).","journal-title":"Pediatr. Res"},{"key":"2843_CR126","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/pr.2014.84","volume":"76","author":"D Choukair","year":"2014","unstructured":"Choukair, D. et al. Inhibition of IGF-I\u2013related intracellular signaling pathways by proinflammatory cytokines in growth plate chondrocytes. Pediatr. Res. 76, 245\u2013251 (2014).","journal-title":"Pediatr. Res."},{"key":"2843_CR127","first-page":"1265","volume":"216","author":"B Yan","year":"2013","unstructured":"Yan, B. et al. miR-206 regulates the growth of the teleost tilapia (Oreochromis niloticus) through the modulation of IGF-1 gene expression. J. Exp. Biol. 216, 1265\u20131269 (2013).","journal-title":"J. Exp. Biol."},{"key":"2843_CR128","doi-asserted-by":"publisher","first-page":"11975","DOI":"10.3390\/cimb46110711","volume":"46","author":"E Al Ageeli","year":"2024","unstructured":"Al Ageeli, E. Dual Roles of microRNA-122 in Hepatocellular Carcinoma and Breast Cancer Progression and Metastasis: A Comprehensive Review. Curr. Issues Mol. Biol. 46, 11975\u201311992 (2024).","journal-title":"Curr. Issues Mol. Biol."},{"key":"2843_CR129","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.canlet.2016.10.023","volume":"385","author":"C Vennin","year":"2017","unstructured":"Vennin, C. et al. The long non-coding RNA 91H increases aggressive phenotype of breast cancer cells and up-regulates H19\/IGF2 expression through epigenetic modifications. Cancer Lett. 385, 198\u2013206 (2017).","journal-title":"Cancer Lett."},{"key":"2843_CR130","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/ncb2521","volume":"14","author":"A Keniry","year":"2012","unstructured":"Keniry, A. et al. The H19 lincRNA is a developmental reservoir of miR-675 that suppresses growth and Igf1r. Nat. Cell Biol. 14, 659\u2013665 (2012).","journal-title":"Nat. Cell Biol."},{"key":"2843_CR131","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41417-021-00313-9","volume":"29","author":"L Wu","year":"2022","unstructured":"Wu, L. et al. Long noncoding RNA LINC01291 promotes the aggressive properties of melanoma by functioning as a competing endogenous RNA for microRNA-625-5p and subsequently increasing IGF-1R expression. Cancer Gene Ther. 29, 341\u2013357 (2022).","journal-title":"Cancer Gene Ther."},{"key":"2843_CR132","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13046-023-02859-y","volume":"42","author":"XR Hsu","year":"2023","unstructured":"Hsu, X. R. et al. Exosomal long noncoding RNA MLETA1 promotes tumor progression and metastasis by regulating the miR-186-5p\/EGFR and miR-497-5p\/IGF1R axes in non-small cell lung cancer. J. Exp. Clin. Cancer Res 42, 283 (2023).","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"2843_CR133","first-page":"234","volume":"41","author":"Z Ma","year":"2026","unstructured":"Ma, Z. et al. LINC00319 promotes cervical cancer progression via targeting miR-147a\/IGF1R pathway. Cancer Biother Radiopharm. 41, 234\u2013243 (2026).","journal-title":"Cancer Biother Radiopharm."},{"key":"2843_CR134","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.21037\/tp-23-424","volume":"12","author":"R Wang","year":"2023","unstructured":"Wang, R. & Gao, Y. Long non-coding RNA growth arrest-specific 5 inhibits liver fibrogenesis in biliary atresia by interacting with microRNA-222 and repressing IGF1\/AKT signaling. Transl. Pediatr. 12, 2107\u20132120 (2023).","journal-title":"Transl. Pediatr."},{"key":"2843_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.mvr.2019.103968","volume":"129","author":"LH Luo","year":"2020","unstructured":"Luo, L. H. et al. Long non-coding RNA NKILA inhibited angiogenesis of breast cancer through NF-\u03baB\/IL-6 signaling pathway. Microvasc. Res. 129, 103968 (2020).","journal-title":"Microvasc. Res."},{"key":"2843_CR136","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2023.2227280","volume":"39","author":"C Chen","year":"2023","unstructured":"Chen, C. et al. Downregulated lncRNA HOTAIR ameliorates polycystic ovaries syndrome via IGF-1 mediated PI3K\/Akt pathway. Gynecol. Endocrinol. 39, 2227280 (2023).","journal-title":"Gynecol. Endocrinol."},{"key":"2843_CR137","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202101317R","volume":"36","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z. et al. Circular RNA circUSP13 sponges miR-29c to promote differentiation and inhibit apoptosis of goat myoblasts by targeting IGF1. FASEB J. 36, e22097 (2022).","journal-title":"FASEB J."},{"key":"2843_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.psj.2022.101803","volume":"101","author":"J Zhao","year":"2022","unstructured":"Zhao, J. et al. CircCCDC91 regulates chicken skeletal muscle development by sponging miR-15 family via activating IGF1-PI3K\/AKT signaling pathway. Poult. Sci. 101, 101803 (2022).","journal-title":"Poult. Sci."},{"key":"2843_CR139","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/nyas.14753","volume":"1512","author":"D Shen","year":"2022","unstructured":"Shen, D. et al. Circular RNA circ_0001459 accelerates hepatocellular carcinoma progression via the miR-6165\/IGF1R axis. Ann. N. Y Acad. Sci. 1512, 46\u201360 (2022).","journal-title":"Ann. N. Y Acad. Sci."},{"key":"2843_CR140","first-page":"233","volume":"35","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. Circ_0014130 participates in the proliferation and apoptosis of nonsmall cell lung cancer cells via the miR-142-5p\/IGF-1 axis. Cancer Biother Radiopharm. 35, 233\u2013240 (2020).","journal-title":"Cancer Biother Radiopharm."},{"key":"2843_CR141","doi-asserted-by":"publisher","first-page":"7635","DOI":"10.1158\/0008-5472.CAN-09-0511","volume":"69","author":"AE Wahner Hendrickson","year":"2009","unstructured":"Wahner Hendrickson, A. E. et al. Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. Cancer Res. 69, 7635\u20137643 (2009).","journal-title":"Cancer Res."},{"key":"2843_CR142","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","volume":"98","author":"MC Petersen","year":"2018","unstructured":"Petersen, M. C. & Shulman, G. I. Mechanisms of insulin action and insulin resistance. Physiol. Rev. 98, 2133\u20132223 (2018).","journal-title":"Physiol. Rev."},{"key":"2843_CR143","doi-asserted-by":"publisher","first-page":"11167","DOI":"10.1074\/jbc.M114.629063","volume":"290","author":"M Muhi\u010d","year":"2015","unstructured":"Muhi\u010d, M. et al. Insulin and insulin-like growth factor 1 (IGF-1) modulate cytoplasmic glucose and glycogen levels but not glucose transport across the membrane in astrocytes. J. Biol. Chem. 290, 11167\u201311176 (2015).","journal-title":"J. Biol. Chem."},{"key":"2843_CR144","doi-asserted-by":"publisher","first-page":"6434","DOI":"10.3390\/ijms22126434","volume":"22","author":"A Kasprzak","year":"2021","unstructured":"Kasprzak, A. Insulin-like growth factor 1 (IGF-1) signaling in glucose metabolism in colorectal cancer. Int. J. Mol. Sci. 22, 6434 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2843_CR145","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S0014-5793(00)02435-2","volume":"488","author":"A Baudry","year":"2001","unstructured":"Baudry, A. et al. IGF-1 receptor as an alternative receptor for metabolic signaling in insulin receptor-deficient muscle cells. FEBS Lett. 488, 174\u2013178 (2001).","journal-title":"FEBS Lett."},{"key":"2843_CR146","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/cen.14461","volume":"95","author":"A Decock","year":"2021","unstructured":"Decock, A. et al. In patients with controlled acromegaly, indices of glucose homeostasis correlate with IGF-1 levels rather than with type of treatment. Clin. Endocrinol. 95, 65\u201373 (2021).","journal-title":"Clin. Endocrinol."},{"key":"2843_CR147","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.3390\/cells10102664","volume":"10","author":"S Al-Samerria","year":"2021","unstructured":"Al-Samerria, S. & Radovick, S. The role of insulin-like growth factor-1 (IGF-1) in the control of neuroendocrine regulation of growth. Cells 10, 2664 (2021).","journal-title":"Cells"},{"key":"2843_CR148","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1210\/clinem\/dgab391","volume":"106","author":"J Cao","year":"2021","unstructured":"Cao, J. et al. Insulin-like growth factor 2 mRNA-binding protein 2-a potential link between type 2 diabetes mellitus and cancer. J. Clin. Endocrinol. Metab. 106, 2807\u20132818 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2843_CR149","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.bbrc.2007.02.012","volume":"355","author":"J Riedemann","year":"2007","unstructured":"Riedemann, J., Takiguchi, M., Sohail, M. & Macaulay, V. M. The EGF receptor interacts with the type 1 IGF receptor and regulates its stability. Biochem. Biophys. Res. Commun. 355, 707\u2013714 (2007).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2843_CR150","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.matbio.2016.06.005","volume":"56","author":"K Voudouri","year":"2016","unstructured":"Voudouri, K. et al. IGF-I\/EGF and E2 signaling crosstalk through IGF-IR conduit point affects breast cancer cell adhesion. Matrix Biol. 56, 95\u2013113 (2016).","journal-title":"Matrix Biol."},{"key":"2843_CR151","doi-asserted-by":"publisher","first-page":"9712","DOI":"10.1158\/0008-5472.CAN-08-1952","volume":"68","author":"NK Saxena","year":"2008","unstructured":"Saxena, N. K. et al. Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res. 68, 9712\u20139722 (2008).","journal-title":"Cancer Res."},{"key":"2843_CR152","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/2159-8290.CD-13-0041","volume":"3","author":"Z Casta\u00f1o","year":"2013","unstructured":"Casta\u00f1o, Z. et al. Stromal EGF and IGF-I together modulate plasticity of disseminated triple-negative breast tumors. Cancer Discov. 3, 922\u2013935 (2013).","journal-title":"Cancer Discov."},{"key":"2843_CR153","doi-asserted-by":"publisher","first-page":"G404","DOI":"10.1152\/ajpgi.00344.2005","volume":"290","author":"M Takaoka","year":"2006","unstructured":"Takaoka, M. et al. EGF-mediated regulation of IGFBP-3 determines esophageal epithelial cellular response to IGF-I. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G404\u2013G416 (2006).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"2843_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2024.102026","volume":"89","author":"T Zhai","year":"2024","unstructured":"Zhai, T. et al. IGFBP2 functions as an endogenous protector against hepatic steatosis via suppression of the EGFR-STAT3 pathway. Mol. Metab. 89, 102026 (2024).","journal-title":"Mol. Metab."},{"key":"2843_CR155","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18442-4","volume":"11","author":"R Wang","year":"2020","unstructured":"Wang, R. et al. Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. Nat. Commun. 11, 4607 (2020).","journal-title":"Nat. Commun."},{"key":"2843_CR156","first-page":"2609","volume":"118","author":"M Guix","year":"2008","unstructured":"Guix, M. et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Investig. 118, 2609\u20132619 (2008).","journal-title":"J. Clin. Investig."},{"key":"2843_CR157","volume":"2","author":"K Park","year":"2021","unstructured":"Park, K. et al. Phase 1b open-label trial of afatinib plus xentuzumab (BI 836845) in patients with EGFR mutation-positive NSCLC after progression on EGFR tyrosine kinase inhibitors. JTO Clin. Res Rep. 2, 100206 (2021).","journal-title":"JTO Clin. Res Rep."},{"key":"2843_CR158","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1006\/excr.1994.1101","volume":"211","author":"M Rubini","year":"1994","unstructured":"Rubini, M. et al. Platelet-derived growth factor increases the activity of the promoter of the insulin-like growth factor-1 (IGF-1) receptor gene. Exp. Cell Res. 211, 374\u2013379 (1994).","journal-title":"Exp. Cell Res."},{"key":"2843_CR159","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/labinvest.3700426","volume":"86","author":"R Novosyadlyy","year":"2006","unstructured":"Novosyadlyy, R. et al. Crosstalk between PDGF and IGF-I receptors in rat liver myofibroblasts: implication for liver fibrogenesis. Lab Investig. 86, 710\u2013723 (2006).","journal-title":"Lab Investig."},{"key":"2843_CR160","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1007\/s00586-007-0408-9","volume":"16","author":"H Pratsinis","year":"2007","unstructured":"Pratsinis, H. & Kletsas, D. PDGF, bFGF and IGF-I stimulate the proliferation of intervertebral disc cells in vitro via the activation of the ERK and Akt signaling pathways. Eur. Spine J. 16, 1858\u20131866 (2007).","journal-title":"Eur. Spine J."},{"key":"2843_CR161","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028663","volume":"6","author":"A Montaseri","year":"2011","unstructured":"Montaseri, A. et al. IGF-1 and PDGF-bb suppress IL-1\u03b2-induced cartilage degradation through down-regulation of NF-\u03baB signaling: involvement of Src\/PI-3K\/AKT pathway. PLoS ONE 6, e28663 (2011).","journal-title":"PLoS ONE"},{"key":"2843_CR162","doi-asserted-by":"publisher","first-page":"31830","DOI":"10.1074\/jbc.M501316200","volume":"280","author":"A Yadav","year":"2005","unstructured":"Yadav, A., Kalita, A., Dhillon, S. & Banerjee, K. JAK\/STAT3 pathway is involved in survival of neurons in response to insulin-like growth factor and negatively regulated by suppressor of cytokine signaling-3. J. Biol. Chem. 280, 31830\u201331840 (2005).","journal-title":"J. Biol. Chem."},{"key":"2843_CR163","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0457-5","volume":"9","author":"Y Zhou","year":"2018","unstructured":"Zhou, Y. et al. Suppressor of cytokine signalling-2 limits IGF1R-mediated regulation of epithelial-mesenchymal transition in lung adenocarcinoma. Cell Death Dis. 9, 429 (2018).","journal-title":"Cell Death Dis."},{"key":"2843_CR164","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/iub.1152","volume":"65","author":"A Kalita","year":"2013","unstructured":"Kalita, A. et al. IGF-1 stimulated upregulation of cyclin D1 is mediated via STAT5 signaling pathway in neuronal cells. IUBMB Life 65, 462\u2013471 (2013).","journal-title":"IUBMB Life"},{"key":"2843_CR165","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1161\/01.RES.85.10.884","volume":"85","author":"T Takahashi","year":"1999","unstructured":"Takahashi, T. et al. Characterization of insulin-like growth factor-1-induced activation of the JAK\/STAT pathway in rat cardiomyocytes. Circ. Res. 85, 884\u2013891 (1999).","journal-title":"Circ. Res."},{"key":"2843_CR166","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.908023","volume":"13","author":"R Nederlof","year":"2022","unstructured":"Nederlof, R. et al. Insulin-like growth factor 1 attenuates the pro-inflammatory phenotype of neutrophils in myocardial infarction. Front. Immunol. 13, 908023 (2022).","journal-title":"Front. Immunol."},{"key":"2843_CR167","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.mce.2017.04.025","volume":"451","author":"PD R\u00e4dler","year":"2017","unstructured":"R\u00e4dler, P. D., Wehde, B. L. & Wagner, K. U. Crosstalk between STAT5 activation and PI3K\/AKT functions in normal and transformed mammary epithelial cells. Mol. Cell Endocrinol. 451, 31\u201339 (2017).","journal-title":"Mol. Cell Endocrinol."},{"key":"2843_CR168","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1038\/onc.2014.164","volume":"34","author":"KM Dodd","year":"2015","unstructured":"Dodd, K. M. et al. mTORC1 drives HIF-1\u03b1 and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene 34, 2239\u20132250 (2015).","journal-title":"Oncogene"},{"key":"2843_CR169","first-page":"455","volume":"59","author":"CS Melincovici","year":"2018","unstructured":"Melincovici, C. S. et al. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Rom. J. Morphol. Embryol. 59, 455\u2013467 (2018).","journal-title":"Rom. J. Morphol. Embryol."},{"key":"2843_CR170","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s11010-024-05010-3","volume":"480","author":"Y Zhao","year":"2025","unstructured":"Zhao, Y. et al. Ang-1 and VEGF: central regulators of angiogenesis. Mol. Cell Biochem. 480, 621\u2013637 (2025).","journal-title":"Mol. Cell Biochem."},{"key":"2843_CR171","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/s41580-023-00631-w","volume":"24","author":"L P\u00e9rez-Guti\u00e9rrez","year":"2023","unstructured":"P\u00e9rez-Guti\u00e9rrez, L. & Ferrara, N. Biology and therapeutic targeting of vascular endothelial growth factor A. Nat. Rev. Mol. Cell Biol. 24, 816\u2013834 (2023).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2843_CR172","doi-asserted-by":"publisher","first-page":"C746","DOI":"10.1152\/ajpcell.00568.2003","volume":"287","author":"MG Slomiany","year":"2004","unstructured":"Slomiany, M. G. & Rosenzweig, S. A. Autocrine effects of IGF-I-induced VEGF and IGFBP-3 secretion in retinal pigment epithelial cell line ARPE-19. Am. J. Physiol. Cell Physiol. 287, C746\u2013C753 (2004).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"2843_CR173","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.semcdb.2021.04.018","volume":"119","author":"HJ Kok","year":"2021","unstructured":"Kok, H. J. & Barton, E. R. Actions and interactions of IGF-I and MMPs during muscle regeneration. Semin Cell Dev. Biol. 119, 11\u201322 (2021).","journal-title":"Semin Cell Dev. Biol."},{"key":"2843_CR174","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1055\/s-0032-1306424","volume":"32","author":"DM Torres","year":"2012","unstructured":"Torres, D. M. & Harrison, S. A. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. Semin Liver Dis. 32, 30\u201338 (2012).","journal-title":"Semin Liver Dis."},{"key":"2843_CR175","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s00432-011-1049-2","volume":"137","author":"C Zhu","year":"2011","unstructured":"Zhu, C. et al. PI3K\/Akt and MAPK\/ERK1\/2 signaling pathways are involved in IGF-1-induced VEGF-C upregulation in breast cancer. J. Cancer Res Clin. Oncol. 137, 1587\u20131594 (2011).","journal-title":"J. Cancer Res Clin. Oncol."},{"key":"2843_CR176","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1359\/jbmr.090602","volume":"24","author":"E Schipani","year":"2009","unstructured":"Schipani, E., Maes, C., Carmeliet, G. & Semenza, G. L. Regulation of osteogenesis-angiogenesis coupling by HIFs and VEGF. J. Bone Min. Res. 24, 1347\u20131353 (2009).","journal-title":"J. Bone Min. Res."},{"key":"2843_CR177","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1089\/ten.tea.2013.0453","volume":"20","author":"C Ferretti","year":"2014","unstructured":"Ferretti, C. et al. Role of IGF1 and IGF1\/VEGF on human mesenchymal stromal cells in bone healing: two sources and two fates. Tissue Eng. Part A 20, 2473\u20132482 (2014).","journal-title":"Tissue Eng. Part A"},{"key":"2843_CR178","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1073\/pnas.0903875106","volume":"107","author":"C Borselli","year":"2010","unstructured":"Borselli, C. et al. Functional muscle regeneration with combined delivery of angiogenesis and myogenesis factors. Proc. Natl. Acad. Sci. USA 107, 3287\u20133292 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2843_CR179","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41413-025-00497-y","volume":"14","author":"J Liao","year":"2026","unstructured":"Liao, J. et al. TGF-beta\/BMP signaling in skeletal biology: molecular mechanisms, regulatory networks, and therapeutic implications in development, regeneration, and disease. Bone Res. 14, 6 (2026).","journal-title":"Bone Res."},{"key":"2843_CR180","doi-asserted-by":"publisher","first-page":"38342","DOI":"10.1074\/jbc.M304583200","volume":"278","author":"K Song","year":"2003","unstructured":"Song, K., Cornelius, S. C., Reiss, M. & Danielpour, D. Insulin-like growth factor-I inhibits transcriptional responses of transforming growth factor-beta by phosphatidylinositol 3-kinase\/Akt-dependent suppression of the activation of Smad3 but not Smad2. J. Biol. Chem. 278, 38342\u201338351 (2003).","journal-title":"J. Biol. Chem."},{"key":"2843_CR181","doi-asserted-by":"publisher","first-page":"12184","DOI":"10.1074\/jbc.M115.680579","volume":"291","author":"T Tando","year":"2016","unstructured":"Tando, T. et al. Smad2\/3 proteins are required for immobilization-induced skeletal muscle atrophy. J. Biol. Chem. 291, 12184\u201312194 (2016).","journal-title":"J. Biol. Chem."},{"key":"2843_CR182","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.mce.2013.06.033","volume":"377","author":"LJ Schedlich","year":"2013","unstructured":"Schedlich, L. J., Yenson, V. M. & Baxter, R. C. TGF-\u03b2-induced expression of IGFBP-3 regulates IGF1R signaling in human osteosarcoma cells. Mol. Cell Endocrinol. 377, 56\u201364 (2013).","journal-title":"Mol. Cell Endocrinol."},{"key":"2843_CR183","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1359\/jbmr.2003.18.6.1066","volume":"18","author":"CO Ortiz","year":"2003","unstructured":"Ortiz, C. O. et al. Transforming growth factor-beta regulation of the insulin-like growth factor binding protein-4 protease system in cultured human osteoblasts. J. Bone Min. Res. 18, 1066\u20131072 (2003).","journal-title":"J. Bone Min. Res."},{"key":"2843_CR184","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1096\/fj.201901719RR","volume":"34","author":"DM Hernandez","year":"2020","unstructured":"Hernandez, D. M. et al. IPF pathogenesis is dependent upon TGF\u03b2 induction of IGF-1. FASEB J. 34, 5363\u20135388 (2020).","journal-title":"FASEB J."},{"key":"2843_CR185","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s10571-020-00977-1","volume":"42","author":"KH Ho","year":"2022","unstructured":"Ho, K. H. et al. miR-4286 is involved in connections between IGF-1 and TGF-\u03b2 signaling for the mesenchymal transition and invasion by glioblastomas. Cell Mol. Neurobiol. 42, 791\u2013806 (2022).","journal-title":"Cell Mol. Neurobiol."},{"key":"2843_CR186","first-page":"53","volume":"20","author":"T Takahashi","year":"2007","unstructured":"Takahashi, T., Morris, E. A. & Trippel, S. B. Bone morphogenetic protein-2 and -9 regulate the interaction of insulin-like growth factor-I with growth plate chondrocytes. Int. J. Mol. Med. 20, 53\u201357 (2007).","journal-title":"Int. J. Mol. Med."},{"key":"2843_CR187","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s11626-025-01015-4","volume":"61","author":"H Ye","year":"2025","unstructured":"Ye, H. & Shao, L. The effect of IGF-1 on cartilage injury in bone marrow mesenchymal stem cells through the BMP2-Smad1\/5 signaling pathway. Vitr. Cell Dev. Biol. Anim. 61, 340\u2013356 (2025).","journal-title":"Vitr. Cell Dev. Biol. Anim."},{"key":"2843_CR188","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1002\/jbmr.133","volume":"25","author":"L Chen","year":"2010","unstructured":"Chen, L. et al. Insulin-like growth factor 2 (IGF-2) potentiates BMP-9-induced osteogenic differentiation and bone formation. J. Bone Min. Res. 25, 2447\u20132459 (2010).","journal-title":"J. Bone Min. Res."},{"key":"2843_CR189","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1242\/jcs.082644","volume":"124","author":"Y Zhong","year":"2011","unstructured":"Zhong, Y. et al. IGF binding protein 3 exerts its ligand-independent action by antagonizing BMP in zebrafish embryos. J. Cell Sci. 124, 1925\u20131935 (2011).","journal-title":"J. Cell Sci."},{"key":"2843_CR190","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.stem.2018.05.018","volume":"22","author":"MY Choi","year":"2018","unstructured":"Choi, M. Y. et al. Phase I trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia. Cell Stem Cell 22, 951\u2013959.e953 (2018).","journal-title":"Cell Stem Cell"},{"key":"2843_CR191","doi-asserted-by":"publisher","first-page":"17266","DOI":"10.1073\/pnas.1419599111","volume":"111","author":"S Zhang","year":"2014","unstructured":"Zhang, S. et al. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc. Natl. Acad. Sci. USA 111, 17266\u201317271 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2843_CR192","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1182\/blood-2016-04-712562","volume":"128","author":"B Cui","year":"2016","unstructured":"Cui, B. et al. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Blood 128, 2931\u20132940 (2016).","journal-title":"Blood"},{"key":"2843_CR193","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.celrep.2018.01.053","volume":"22","author":"VD Gonzalez","year":"2018","unstructured":"Gonzalez, V. D. et al. Commonly occurring cell subsets in high-grade serous ovarian tumors identified by single-cell mass cytometry. Cell Rep. 22, 1875\u20131888 (2018).","journal-title":"Cell Rep."},{"key":"2843_CR194","doi-asserted-by":"publisher","first-page":"7828","DOI":"10.3390\/ijms26167828","volume":"26","author":"MS Jung","year":"2025","unstructured":"Jung, M. S. et al. The role of receptor tyrosine kinase-like orphan receptor 1 (ROR1) in cancer stem cell signaling. Int. J. Mol. Sci. 26, 7828 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"2843_CR195","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37306-1","volume":"14","author":"W Lin","year":"2023","unstructured":"Lin, W. et al. IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1\/HER2-CREB signaling axis. Nat. Commun. 14, 1578 (2023).","journal-title":"Nat. Commun."},{"key":"2843_CR196","doi-asserted-by":"publisher","first-page":"11118","DOI":"10.1158\/0008-5472.CAN-04-3841","volume":"65","author":"R Nahta","year":"2005","unstructured":"Nahta, R. et al. Insulin-like growth factor-I receptor\/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 65, 11118\u201311128 (2005).","journal-title":"Cancer Res."},{"key":"2843_CR197","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.gendis.2022.07.011","volume":"10","author":"R Vlashi","year":"2023","unstructured":"Vlashi, R., Zhang, X., Wu, M. & Chen, G. Wnt signaling: Essential roles in osteoblast differentiation, bone metabolism and therapeutic implications for bone and skeletal disorders. Genes Dis. 10, 1291\u20131317 (2023).","journal-title":"Genes Dis."},{"key":"2843_CR198","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202500030R","volume":"39","author":"C Zheng","year":"2025","unstructured":"Zheng, C. et al. Cbfbeta: a key regulator in skeletal stem cell differentiation, bone development, and disease. FASEB J. 39, e70399 (2025).","journal-title":"FASEB J."},{"key":"2843_CR199","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ydbio.2023.06.015","volume":"501","author":"S Hu","year":"2023","unstructured":"Hu, S. et al. Ap-2beta regulates cranial osteogenic potential via the activation of Wnt\/beta-catenin signaling pathway. Dev. Biol. 501, 81\u201391 (2023).","journal-title":"Dev. Biol."},{"key":"2843_CR200","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-025-02191-2","volume":"23","author":"MJ Kim","year":"2025","unstructured":"Kim, M. J. et al. IGF-1 promotes trophectoderm cell proliferation of porcine embryos by activating the Wnt\/\u03b2-catenin pathway. Cell Commun. Signal. 23, 188 (2025).","journal-title":"Cell Commun. Signal."},{"key":"2843_CR201","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1158\/0008-5472.CAN-14-0970","volume":"74","author":"LM Rota","year":"2014","unstructured":"Rota, L. M. et al. IGF1R inhibition in mammary epithelia promotes canonical Wnt signaling and Wnt1-driven tumors. Cancer Res. 74, 5668\u20135679 (2014).","journal-title":"Cancer Res."},{"key":"2843_CR202","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/ncb2607","volume":"14","author":"R Chakrabarti","year":"2012","unstructured":"Chakrabarti, R. et al. Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat. Cell Biol. 14, 1212\u20131222 (2012).","journal-title":"Nat. Cell Biol."},{"key":"2843_CR203","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1084\/jem.20110121","volume":"208","author":"H Medyouf","year":"2011","unstructured":"Medyouf, H. et al. High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. J. Exp. Med. 208, 1809\u20131822 (2011).","journal-title":"J. Exp. Med."},{"key":"2843_CR204","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1073\/pnas.0600065103","volume":"103","author":"A Ayyanan","year":"2006","unstructured":"Ayyanan, A. et al. Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. Proc. Natl. Acad. Sci. USA 103, 3799\u20133804 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2843_CR205","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202402545R","volume":"39","author":"M Dilawar","year":"2025","unstructured":"Dilawar, M. et al. Notch signaling pathway in osteogenesis, bone development, metabolism, and diseases. FASEB J. 39, e70417 (2025).","journal-title":"FASEB J."},{"key":"2843_CR206","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetpar.2025.110390","volume":"334","author":"N Bonadeo","year":"2025","unstructured":"Bonadeo, N. et al. NOTCH and IGF1 signaling systems are involved in the effects exerted by anthelminthic treatment of heifers on the bovine mammary gland. Vet. Parasitol. 334, 110390 (2025).","journal-title":"Vet. Parasitol."},{"key":"2843_CR207","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41420-019-0166-6","volume":"5","author":"E Acaz-Fonseca","year":"2019","unstructured":"Acaz-Fonseca, E. et al. Notch signaling in astrocytes mediates their morphological response to an inflammatory challenge. Cell Death Discov. 5, 85 (2019).","journal-title":"Cell Death Discov."},{"key":"2843_CR208","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygcen.2024.114657","volume":"361","author":"Y Nozawa","year":"2025","unstructured":"Nozawa, Y. et al. Crosstalk between prolactin, insulin-like growth factors, and thyroid hormones in feather growth regulation in neonatal chick wings. Gen. Comp. Endocrinol. 361, 114657 (2025).","journal-title":"Gen. Comp. Endocrinol."},{"key":"2843_CR209","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1007\/s12032-012-0198-8","volume":"29","author":"H Tang","year":"2012","unstructured":"Tang, H. et al. Estrogen upregulates the IGF-1 signaling pathway in lung cancer through estrogen receptor-\u03b2. Med Oncol. 29, 2640\u20132648 (2012).","journal-title":"Med Oncol."},{"key":"2843_CR210","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1158\/1078-0432.CCR-14-0902","volume":"20","author":"E Weisberg","year":"2014","unstructured":"Weisberg, E. et al. Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R. Clin. Cancer Res. 20, 5483\u20135495 (2014).","journal-title":"Clin. Cancer Res."},{"key":"2843_CR211","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1756-8722-6-72","volume":"6","author":"X Chen","year":"2013","unstructured":"Chen, X. et al. IGF binding protein 2 is a cell-autonomous factor supporting survival and migration of acute leukemia cells. J. Hematol. Oncol. 6, 72 (2013).","journal-title":"J. Hematol. Oncol."},{"key":"2843_CR212","doi-asserted-by":"publisher","first-page":"6368","DOI":"10.1182\/bloodadvances.2020002812","volume":"4","author":"N van Gils","year":"2020","unstructured":"van Gils, N. et al. IGFBP7 activates retinoid acid-induced responses in acute myeloid leukemia stem and progenitor cells. Blood Adv. 4, 6368\u20136383 (2020).","journal-title":"Blood Adv."},{"key":"2843_CR213","doi-asserted-by":"publisher","first-page":"10137","DOI":"10.3748\/wjg.v21.i35.10137","volume":"21","author":"T Lei","year":"2015","unstructured":"Lei, T. & Ling, X. IGF-1 promotes the growth and metastasis of hepatocellular carcinoma via the inhibition of proteasome-mediated cathepsin B degradation. World J. Gastroenterol. 21, 10137\u201310149 (2015).","journal-title":"World J. Gastroenterol."},{"key":"2843_CR214","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3748\/wjg.v9.i2.267","volume":"9","author":"Z Wang","year":"2003","unstructured":"Wang, Z., Ruan, Y. B., Guan, Y. & Liu, S. H. Expression of IGF-II in early experimental hepatocellular carcinomas and its significance in early diagnosis. World J. Gastroenterol. 9, 267\u2013270 (2003).","journal-title":"World J. Gastroenterol."},{"key":"2843_CR215","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202105120","volume":"9","author":"D Kumar","year":"2022","unstructured":"Kumar, D. et al. Hepatocyte deletion of IGF2 prevents dna damage and tumor formation in hepatocellular carcinoma. Adv. Sci. 9, e2105120 (2022).","journal-title":"Adv. Sci."},{"key":"2843_CR216","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101305","volume":"7","author":"M Gjorgjieva","year":"2025","unstructured":"Gjorgjieva, M. et al. Hepatic IR and IGF1R signaling govern distinct metabolic and carcinogenic processes upon PTEN deficiency in the liver. JHEP Rep. 7, 101305 (2025).","journal-title":"JHEP Rep."},{"key":"2843_CR217","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1007\/s12672-025-02890-9","volume":"16","author":"Q Tian","year":"2025","unstructured":"Tian, Q. et al. IGF1\/IGF1R signaling promotes the expansion of liver CSCs and serves as a potential therapeutic target in HCC. Discov. Oncol. 16, 1058 (2025).","journal-title":"Discov. Oncol."},{"key":"2843_CR218","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1158\/0008-5472.CAN-16-2885","volume":"77","author":"M Akiel","year":"2017","unstructured":"Akiel, M. et al. IGFBP7 deletion promotes hepatocellular carcinoma. Cancer Res 77, 4014\u20134025 (2017).","journal-title":"Cancer Res"},{"key":"2843_CR219","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1038\/s41388-022-02376-w","volume":"41","author":"E Alfaro-Arnedo","year":"2022","unstructured":"Alfaro-Arnedo, E. et al. IGF1R acts as a cancer-promoting factor in the tumor microenvironment facilitating lung metastasis implantation and progression. Oncogene 41, 3625\u20133639 (2022).","journal-title":"Oncogene"},{"key":"2843_CR220","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abj5879","volume":"15","author":"LL Remsing Rix","year":"2022","unstructured":"Remsing Rix, L. L. et al. IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells. Sci. Signal. 15, eabj5879 (2022).","journal-title":"Sci. Signal."},{"key":"2843_CR221","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1158\/1541-7786.MCR-16-0390","volume":"15","author":"YA Wang","year":"2017","unstructured":"Wang, Y. A. et al. IGFBP3 modulates lung tumorigenesis and cell growth through IGF1 signaling. Mol. Cancer Res. 15, 896\u2013904 (2017).","journal-title":"Mol. Cancer Res."},{"key":"2843_CR222","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3171\/2018.8.JNS181217","volume":"132","author":"CH Chen","year":"2020","unstructured":"Chen, C. H. et al. Suppression of tumor growth via IGFBP3 depletion as a potential treatment in glioma. J. Neurosurg. 132, 168\u2013179 (2020).","journal-title":"J. Neurosurg."},{"key":"2843_CR223","doi-asserted-by":"publisher","first-page":"11736","DOI":"10.1073\/pnas.0703145104","volume":"104","author":"SM Dunlap","year":"2007","unstructured":"Dunlap, S. M. et al. Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc. Natl. Acad. Sci. USA 104, 11736\u201311741 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2843_CR224","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.52322","volume":"9","author":"C Liu","year":"2020","unstructured":"Liu, C. et al. The metalloproteinase Papp-aa controls epithelial cell quiescence-proliferation transition. Elife 9, e52322 (2020).","journal-title":"Elife"},{"key":"2843_CR225","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature21039","volume":"542","author":"E Marouli","year":"2017","unstructured":"Marouli, E. et al. Rare and low-frequency coding variants alter human adult height. Nature 542, 186\u2013190 (2017).","journal-title":"Nature"},{"key":"2843_CR226","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1210\/en.2015-1668","volume":"156","author":"BP Garfinkel","year":"2015","unstructured":"Garfinkel, B. P. et al. Proportionate dwarfism in mice lacking heterochromatin protein 1 binding protein 3 (HP1BP3) is associated with alterations in the endocrine IGF-1 pathway. Endocrinology 156, 4558\u20134570 (2015).","journal-title":"Endocrinology"},{"key":"2843_CR227","doi-asserted-by":"publisher","first-page":"RP90949","DOI":"10.7554\/eLife.90949.3","volume":"12","author":"DC Sarver","year":"2024","unstructured":"Sarver, D. C. et al. Tmem263 deletion disrupts the GH\/IGF-1 axis and causes dwarfism and impairs skeletal acquisition. eLife 12, RP90949 (2024).","journal-title":"eLife"},{"key":"2843_CR228","doi-asserted-by":"publisher","first-page":"108729","DOI":"10.1016\/j.celrep.2021.108729","volume":"34","author":"J Liao","year":"2021","unstructured":"Liao, J. et al. Prenatal correction of IGF2 to rescue the growth phenotypes in mouse models of Beckwith-Wiedemann and Silver-Russell syndromes. Cell Rep. 34, 108729 (2021).","journal-title":"Cell Rep."},{"key":"2843_CR229","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1002\/jbmr.2510","volume":"30","author":"T Wang","year":"2015","unstructured":"Wang, T. et al. Osteoblast-specific loss of IGF1R signaling results in impaired endochondral bone formation during fracture healing. J. Bone Min. Res. 30, 1572\u20131584 (2015).","journal-title":"J. Bone Min. Res."},{"key":"2843_CR230","doi-asserted-by":"publisher","DOI":"10.1038\/boneres.2014.12","volume":"2","author":"F Zhang","year":"2014","unstructured":"Zhang, F. et al. Insulin exerts direct, IGF-1 independent actions in growth plate chondrocytes. Bone Res. 2, 14012 (2014).","journal-title":"Bone Res."},{"key":"2843_CR231","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.1007\/s11357-025-01653-2","volume":"47","author":"A Nyul-Toth","year":"2025","unstructured":"Nyul-Toth, A. et al. Endothelial IGF- 1R deficiency disrupts microvascular homeostasis, impairing skeletal muscle perfusion and endurance: implications for age-related sarcopenia. GeroScience 47, 4187\u20134204 (2025).","journal-title":"GeroScience"},{"key":"2843_CR232","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116600","volume":"166","author":"A Esposito","year":"2023","unstructured":"Esposito, A. et al. CXCR4 mediates the effects of IGF-1R signaling in rodent bone homeostasis and fracture repair. Bone 166, 116600 (2023).","journal-title":"Bone"},{"key":"2843_CR233","doi-asserted-by":"publisher","first-page":"E1191","DOI":"10.1152\/ajpendo.00440.2011","volume":"301","author":"C Kesavan","year":"2011","unstructured":"Kesavan, C., Wergedal, J. E., Lau, K. H. & Mohan, S. Conditional disruption of IGF-I gene in type 1\u03b1 collagen-expressing cells shows an essential role of IGF-I in skeletal anabolic response to loading. Am. J. Physiol. Endocrinol. Metab. 301, E1191\u2013E1197 (2011).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"2843_CR234","doi-asserted-by":"publisher","first-page":"6984","DOI":"10.1007\/s00464-022-09069-1","volume":"36","author":"BT Harris","year":"2022","unstructured":"Harris, B. T. et al. Insulin-like growth factor binding protein 2 null mice (Igfbp2-\/-) are protected against trabecular bone loss after vertical sleeve gastrectomy. Surg. Endosc. 36, 6984\u20136996 (2022).","journal-title":"Surg. Endosc."},{"key":"2843_CR235","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202406965","volume":"12","author":"S Sun","year":"2025","unstructured":"Sun, S. et al. Delayed administration of IGFBP7 improved bone defect healing via ZO-1 dependent vessel stabilization. Adv. Sci. 12, e2406965 (2025).","journal-title":"Adv. Sci."},{"key":"2843_CR236","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1096\/fj.201800459R","volume":"33","author":"G Vassilakos","year":"2019","unstructured":"Vassilakos, G. et al. Deletion of muscle IGF-I transiently impairs growth and progressively disrupts glucose homeostasis in male mice. FASEB J. 33, 181\u2013194 (2019).","journal-title":"FASEB J."},{"key":"2843_CR237","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2208855119","volume":"119","author":"F Fang","year":"2022","unstructured":"Fang, F. et al. Unexpected role for IGF-1 in starvation: Maintenance of blood glucose. Proc. Natl. Acad. Sci. USA 119, e2208855119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2843_CR238","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.2337\/db07-1538","volume":"57","author":"N Kl\u00f6ting","year":"2008","unstructured":"Kl\u00f6ting, N. et al. Autocrine IGF-1 action in adipocytes controls systemic IGF-1 concentrations and growth. Diabetes 57, 2074\u20132082 (2008).","journal-title":"Diabetes"},{"key":"2843_CR239","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.2337\/db16-0212","volume":"65","author":"J Boucher","year":"2016","unstructured":"Boucher, J. et al. Differential roles of insulin and IGF-1 receptors in adipose tissue development and function. Diabetes 65, 2201\u20132213 (2016).","journal-title":"Diabetes"},{"key":"2843_CR240","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54669-1","volume":"16","author":"C Luk","year":"2025","unstructured":"Luk, C. et al. Paracrine role of endothelial IGF-1 receptor in depot-specific adipose tissue adaptation in male mice. Nat. Commun. 16, 170 (2025).","journal-title":"Nat. Commun."},{"key":"2843_CR241","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2025.156355","volume":"171","author":"AJ L\u00f3pez-Gambero","year":"2025","unstructured":"L\u00f3pez-Gambero, A. J. et al. Alteration of IGF-1 bioavailability due to PAPPA2 deficiency leads to sex-specific metabolic disturbances. Metabolism 171, 156355 (2025).","journal-title":"Metabolism"},{"key":"2843_CR242","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jhep.2013.03.037","volume":"59","author":"X Xu","year":"2013","unstructured":"Xu, X., Hueckstaedt, L. K. & Ren, J. Deficiency of insulin-like growth factor 1 attenuates aging-induced changes in hepatic function: role of autophagy. J. Hepatol. 59, 308\u2013317 (2013).","journal-title":"J. Hepatol."},{"key":"2843_CR243","doi-asserted-by":"publisher","first-page":"627","DOI":"10.2353\/ajpath.2009.081081","volume":"175","author":"A Cadoret","year":"2009","unstructured":"Cadoret, A. et al. IGF-1R contributes to stress-induced hepatocellular damage in experimental cholestasis. Am. J. Pathol. 175, 627\u2013635 (2009).","journal-title":"Am. J. Pathol."},{"key":"2843_CR244","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1096\/fj.05-4704fje","volume":"20","author":"C Desbois-Mouthon","year":"2006","unstructured":"Desbois-Mouthon, C. et al. Hepatocyte proliferation during liver regeneration is impaired in mice with liver-specific IGF-1R knockout. FASEB J. 20, 773\u2013775 (2006).","journal-title":"FASEB J."},{"key":"2843_CR245","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jcmgh.2020.05.005","volume":"10","author":"U Yaqoob","year":"2020","unstructured":"Yaqoob, U. et al. GIPC-regulated IGFBP-3 promotes HSC migration in vitro and portal hypertension in vivo through a \u03b21-integrin pathway. Cell Mol. Gastroenterol. Hepatol. 10, 545\u2013559 (2020).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"2843_CR246","doi-asserted-by":"publisher","first-page":"H284","DOI":"10.1152\/ajpheart.00904.2009","volume":"299","author":"CA Conover","year":"2010","unstructured":"Conover, C. A. et al. Transgenic overexpression of pregnancy-associated plasma protein-A in murine arterial smooth muscle accelerates atherosclerotic lesion development. Am. J. Physiol. Heart Circ. Physiol. 299, H284\u2013H291 (2010).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2843_CR247","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.ajpath.2010.10.007","volume":"178","author":"JH von der Th\u00fcsen","year":"2011","unstructured":"von der Th\u00fcsen, J. H. et al. IGF-1 has plaque-stabilizing effects in atherosclerosis by altering vascular smooth muscle cell phenotype. Am. J. Pathol. 178, 924\u2013934 (2011).","journal-title":"Am. J. Pathol."},{"key":"2843_CR248","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.116.021805","volume":"133","author":"Y Higashi","year":"2016","unstructured":"Higashi, Y. et al. Insulin-like growth factor-1 receptor deficiency in macrophages accelerates atherosclerosis and induces an unstable plaque phenotype in apolipoprotein E\u2013deficient mice. Circulation 133, 2263\u20132278 (2016).","journal-title":"Circulation"},{"key":"2843_CR249","doi-asserted-by":"publisher","first-page":"e165713","DOI":"10.1172\/jci.insight.165713","volume":"8","author":"S Sukhanov","year":"2023","unstructured":"Sukhanov, S. et al. Insulin-like growth factor 1 reduces coronary atherosclerosis in pigs with familial hypercholesterolemia. JCI insight 8, e165713 (2023).","journal-title":"JCI insight"},{"key":"2843_CR250","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvz006","volume":"4","author":"NJ Haywood","year":"2020","unstructured":"Haywood, N. J. et al. IGFBP-1 in cardiometabolic pathophysiology-insights from loss-of-function and gain-of-function studies in male mice. J. Endocr. Soc. 4, bvz006 (2020).","journal-title":"J. Endocr. Soc."},{"key":"2843_CR251","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111409","volume":"127","author":"W Wang","year":"2024","unstructured":"Wang, W. et al. The effects of IGF-1 and IGFBP-2 treatments on the atherosclerosis in the aorta and the coronary arteries of the high cholesterol diet-fed rabbits. Int Immunopharmacol. 127, 111409 (2024).","journal-title":"Int Immunopharmacol."},{"key":"2843_CR252","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s44161-024-00591-0","volume":"4","author":"M Su","year":"2025","unstructured":"Su, M. et al. Endothelial IGFBP6 suppresses vascular inflammation and atherosclerosis. Nat. Cardiovasc Res 4, 145\u2013162 (2025).","journal-title":"Nat. Cardiovasc Res"},{"key":"2843_CR253","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ymthe.2018.10.020","volume":"27","author":"A Heinen","year":"2019","unstructured":"Heinen, A. et al. IGF1 treatment improves cardiac remodeling after infarction by targeting myeloid cells. Mol. Ther. 27, 46\u201358 (2019).","journal-title":"Mol. Ther."},{"key":"2843_CR254","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41420-021-00629-3","volume":"7","author":"X Tang","year":"2021","unstructured":"Tang, X. et al. Insulin-like growth factor binding protein-1 regulates HIF-1\u03b1 degradation to inhibit apoptosis in hypoxic cardiomyocytes. Cell Death Discov. 7, 242 (2021).","journal-title":"Cell Death Discov."},{"key":"2843_CR255","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1038\/s42003-024-07304-0","volume":"7","author":"Q Zhu","year":"2024","unstructured":"Zhu, Q. et al. IGFBP5 affects cardiomyocyte survival and functional recovery in mice following myocardial ischemia. Commun. Biol. 7, 1594 (2024).","journal-title":"Commun. Biol."},{"key":"2843_CR256","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1210\/endo.140.7.7045","volume":"140","author":"J Wang","year":"1999","unstructured":"Wang, J., Zhou, J., Powell-Braxton, L. & Bondy, C. Effects of Igf1 gene deletion on postnatal growth patterns. Endocrinology 140, 3391\u20133394 (1999).","journal-title":"Endocrinology"},{"key":"2843_CR257","doi-asserted-by":"publisher","first-page":"171418","DOI":"10.1016\/j.peptides.2025.171418","volume":"190","author":"K Banjac","year":"2025","unstructured":"Banjac, K., Obradovic, M., Zafirovic, S. & Isenovic, E. R. IGF-1 contributes to cardiovascular protection in obesity by upregulating Na+\/K+-ATPase activity and modulating key signaling pathways in rats on a high-fat diet. Peptides 190, 171418 (2025).","journal-title":"Peptides"},{"key":"2843_CR258","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1128\/MCB.01110-06","volume":"27","author":"PG Laustsen","year":"2007","unstructured":"Laustsen, P. G. et al. Essential role of insulin and insulin-like growth factor 1 receptor signaling in cardiac development and function. Mol. Cell Biol. 27, 1649\u20131664 (2007).","journal-title":"Mol. Cell Biol."},{"key":"2843_CR259","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1750-1326-6-41","volume":"6","author":"G Marwarha","year":"2011","unstructured":"Marwarha, G. et al. Molecular interplay between leptin, insulin-like growth factor-1, and \u03b2-amyloid in organotypic slices from rabbit hippocampus. Mol. Neurodegener. 6, 41 (2011).","journal-title":"Mol. Neurodegener."},{"key":"2843_CR260","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1017\/S1041610219000383","volume":"31","author":"L Xia","year":"2019","unstructured":"Xia, L. et al. Genome-wide RNA sequencing analysis reveals that IGF-2 attenuates memory decline, oxidative stress and amyloid plaques in an Alzheimer\u2019s disease mouse model (AD) by activating the PI3K\/AKT\/CREB signaling pathway. Int. Psychogeriatr. 31, 947\u2013959 (2019).","journal-title":"Int. Psychogeriatr."},{"key":"2843_CR261","doi-asserted-by":"publisher","first-page":"1520253","DOI":"10.3389\/fncel.2024.1520253","volume":"18","author":"R Chen","year":"2024","unstructured":"Chen, R., Lu, X., Xiao, A. & Ma, J. Role of insulin-like growth factor-2 in Alzheimer\u2019s disease induced memory impairment and underlying mechanisms. Front. Cell Neurosci. 18, 1520253 (2024).","journal-title":"Front. Cell Neurosci."},{"key":"2843_CR262","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2023.137189","volume":"808","author":"M Wang","year":"2023","unstructured":"Wang, M. et al. Down-regulating insulin-like growth factor-1 receptor reduces amyloid-\u03b2 deposition in mice cortex induced by chronic sleep restriction. Neurosci. Lett. 808, 137189 (2023).","journal-title":"Neurosci. Lett."},{"key":"2843_CR263","doi-asserted-by":"publisher","first-page":"11500","DOI":"10.1523\/JNEUROSCI.0343-15.2015","volume":"35","author":"G Gontier","year":"2015","unstructured":"Gontier, G. et al. Blocking IGF signaling in adult neurons alleviates Alzheimer\u2019s disease pathology through amyloid-\u03b2 clearance. J. Neurosci. 35, 11500\u201311513 (2015).","journal-title":"J. Neurosci."},{"key":"2843_CR264","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.54781","volume":"9","author":"X-W Yu","year":"2020","unstructured":"Yu, X.-W., Pandey, K., Katzman, A. C. & Alberini, C. M. A role for CIM6P\/IGF2 receptor in memory consolidation and enhancement. eLife 9, e54781 (2020).","journal-title":"eLife"},{"key":"2843_CR265","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1007\/s12035-024-04457-1","volume":"62","author":"J Miao","year":"2025","unstructured":"Miao, J. et al. Insulin-like growth factor signaling in alzheimer\u2019s disease: pathophysiology and therapeutic strategies. Mol. Neurobiol. 62, 3195\u20133225 (2025).","journal-title":"Mol. Neurobiol."},{"key":"2843_CR266","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1016\/j.bbadis.2017.06.002","volume":"1863","author":"MC Erlandsson","year":"2017","unstructured":"Erlandsson, M. C. et al. IGF-1R signalling contributes to IL-6 production and T cell dependent inflammation in rheumatoid arthritis. Biochim. Biophys. Acta Mol. Basis Dis. 1863, 2158\u20132170 (2017).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"2843_CR267","first-page":"14","volume":"15","author":"E Abdi","year":"2018","unstructured":"Abdi, E. et al. Expression of IGF-1, IL-27 and IL-35 receptors in adjuvant induced rheumatoid arthritis model. Iran. J. Immunol. 15, 14\u201327 (2018).","journal-title":"Iran. J. Immunol."},{"key":"2843_CR268","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/art.38303","volume":"66","author":"HS Lee","year":"2014","unstructured":"Lee, H. S. et al. Regulation of apoptosis and inflammatory responses by insulin-like growth factor binding protein 3 in fibroblast-like synoviocytes and experimental animal models of rheumatoid arthritis. Arthritis Rheumatol. 66, 863\u2013873 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"2843_CR269","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/cei.12743","volume":"184","author":"H Ding","year":"2016","unstructured":"Ding, H., Kharboutli, M., Saxena, R. & Wu, T. Insulin-like growth factor binding protein-2 as a novel biomarker for disease activity and renal pathology changes in lupus nephritis. Clin. Exp. Immunol. 184, 11\u201318 (2016).","journal-title":"Clin. Exp. Immunol."},{"key":"2843_CR270","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1191\/0961203303lu422oa","volume":"12","author":"J Mohammed","year":"2003","unstructured":"Mohammed, J., Mok, A. Y., Parbtani, A. & Matsell, D. Increased expression of insulin-like growth factors in progressive glomerulonephritis of the MRL lpr mouse. Lupus 12, 584\u2013590 (2003).","journal-title":"Lupus"},{"key":"2843_CR271","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s00109-022-02241-z","volume":"100","author":"H Li","year":"2022","unstructured":"Li, H. et al. IGFBP2 function as a novel biomarker for active lupus nephritis. J. Mol. Med. 100, 1479\u20131491 (2022).","journal-title":"J. Mol. Med."},{"key":"2843_CR272","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/0006-2952(95)00017-T","volume":"49","author":"M Kerr","year":"1995","unstructured":"Kerr, M. et al. Detection of insulin and insulin-like growth factors I and II in saliva and potential synthesis in the salivary glands of mice. Effects of type 1 diabetes mellitus. Biochem. Pharmacol. 49, 1521\u20131531 (1995).","journal-title":"Biochem. Pharmacol."},{"key":"2843_CR273","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/0022034516677529","volume":"96","author":"S Meyer","year":"2017","unstructured":"Meyer, S., Chibly, A. M., Burd, R. & Limesand, K. H. Insulin-like growth factor-1-mediated DNA repair in irradiated salivary glands is sirtuin-1 dependent. J. Dent. Res. 96, 225\u2013232 (2017).","journal-title":"J. Dent. Res."},{"key":"2843_CR274","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1007\/s11357-022-00623-2","volume":"44","author":"L Toth","year":"2022","unstructured":"Toth, L. et al. Age-related decline in circulating IGF-1 associates with impaired neurovascular coupling responses in older adults. Geroscience 44, 2771\u20132783 (2022).","journal-title":"Geroscience"},{"key":"2843_CR275","first-page":"9","volume":"366","author":"C Kenyon","year":"2011","unstructured":"Kenyon, C. The first long-lived mutants: discovery of the insulin\/IGF-1 pathway for ageing. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 366, 9\u201316 (2011).","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"key":"2843_CR276","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.1057991","volume":"292","author":"DJ Clancy","year":"2001","unstructured":"Clancy, D. J. et al. Extension of life-span by loss of CHICO, a Drosophila insulin receptor substrate protein. Science 292, 104\u2013106 (2001).","journal-title":"Science"},{"key":"2843_CR277","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04805-5","volume":"9","author":"K Mao","year":"2018","unstructured":"Mao, K. et al. Late-life targeting of the IGF-1 receptor improves healthspan and lifespan in female mice. Nat. Commun. 9, 2394 (2018).","journal-title":"Nat. Commun."},{"key":"2843_CR278","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/nrendo.2013.67","volume":"9","author":"RK Junnila","year":"2013","unstructured":"Junnila, R. K. et al. The GH\/IGF-1 axis in ageing and longevity. Nat. Rev. Endocrinol. 9, 366\u2013376 (2013).","journal-title":"Nat. Rev. Endocrinol."},{"key":"2843_CR279","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-8-353","volume":"8","author":"WR Swindell","year":"2007","unstructured":"Swindell, W. R. Gene expression profiling of long-lived dwarf mice: longevity-associated genes and relationships with diet, gender and aging. BMC Genomics 8, 353 (2007).","journal-title":"BMC Genomics"},{"key":"2843_CR280","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.etap.2018.03.014","volume":"59","author":"S Hong","year":"2018","unstructured":"Hong, S. & Kim, M. M. IGFBP-3 plays an important role in senescence as an aging marker. Environ. Toxicol. Pharm. 59, 138\u2013145 (2018).","journal-title":"Environ. Toxicol. Pharm."},{"key":"2843_CR281","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/acel.12624","volume":"16","author":"LK Bale","year":"2017","unstructured":"Bale, L. K., West, S. A. & Conover, C. A. Inducible knockdown of pregnancy-associated plasma protein-A gene expression in adult female mice extends life span. Aging Cell 16, 895\u2013897 (2017).","journal-title":"Aging Cell"},{"key":"2843_CR282","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.exger.2015.08.007","volume":"70","author":"CA Conover","year":"2015","unstructured":"Conover, C. A., Bale, L. K. & Marler, R. J. Pregnancy-associated plasma protein-A deficiency improves survival of mice on a high fat diet. Exp. Gerontol. 70, 131\u2013134 (2015).","journal-title":"Exp. Gerontol."},{"key":"2843_CR283","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.canlet.2014.11.052","volume":"357","author":"J Zhang","year":"2015","unstructured":"Zhang, J. et al. SUMOylation of insulin-like growth factor 1 receptor, promotes proliferation in acute myeloid leukemia. Cancer Lett. 357, 297\u2013306 (2015).","journal-title":"Cancer Lett."},{"key":"2843_CR284","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1540426","volume":"15","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. Advances in the role of the IGF signaling system in myelodysplastic syndromes and acute myeloid leukemia. Front. Oncol. 15, 1540426 (2025).","journal-title":"Front. Oncol."},{"key":"2843_CR285","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3324\/haematol.2009.010785","volume":"95","author":"N Chapuis","year":"2009","unstructured":"Chapuis, N. et al. Autocrine IGF-1\/IGF-1R signaling is responsible for constitutive PI3K\/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica 95, 415 (2009).","journal-title":"Haematologica"},{"key":"2843_CR286","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.canlet.2018.10.028","volume":"442","author":"JM Zhang","year":"2019","unstructured":"Zhang, J. M. et al. ADAM28 promotes tumor growth and dissemination of acute myeloid leukemia through IGFBP-3 degradation and IGF-I-induced cell proliferation. Cancer Lett. 442, 193\u2013201 (2019).","journal-title":"Cancer Lett."},{"key":"2843_CR287","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3389\/fphar.2018.00687","volume":"9","author":"DD Xu","year":"2018","unstructured":"Xu, D. D. et al. The IGF2\/IGF1R\/nanog signaling pathway regulates the proliferation of acute myeloid leukemia stem cells. Front. Pharm. 9, 687 (2018).","journal-title":"Front. Pharm."},{"key":"2843_CR288","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.ccell.2018.08.016","volume":"34","author":"H Ye","year":"2018","unstructured":"Ye, H. et al. Subversion of systemic glucose metabolism as a mechanism to support the growth of leukemia cells. Cancer Cell 34, 659\u2013673. e656 (2018).","journal-title":"Cancer Cell"},{"key":"2843_CR289","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.3109\/10428194.2015.1022767","volume":"56","author":"R Karmali","year":"2015","unstructured":"Karmali, R. et al. Impact of insulin-like growth factor 1 and insulin-like growth factor binding proteins on outcomes in acute myeloid leukemia. Leuk. Lymphoma 56, 3135\u20133142 (2015).","journal-title":"Leuk. Lymphoma"},{"key":"2843_CR290","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.leukres.2011.08.006","volume":"35","author":"A K\u00fchnl","year":"2011","unstructured":"K\u00fchnl, A. et al. High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia. Leuk. Res. 35, 1585\u20131590 (2011).","journal-title":"Leuk. Res."},{"key":"2843_CR291","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/pbc.21294","volume":"50","author":"K Dawczynski","year":"2008","unstructured":"Dawczynski, K. et al. Expression of components of the IGF axis in childhood acute myelogenous leukemia. Pediatr. Blood Cancer 50, 24\u201328 (2008).","journal-title":"Pediatr. Blood Cancer"},{"key":"2843_CR292","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2023.100952","volume":"47","author":"B Zhang","year":"2024","unstructured":"Zhang, B. et al. Secreted insulin-like growth factor binding protein 5 functions as a tumor suppressor and chemosensitizer through inhibiting insulin-like growth factor 1 receptor\/protein kinase B pathway in acute myeloid leukemia. Neoplasia 47, 100952 (2024).","journal-title":"Neoplasia"},{"key":"2843_CR293","doi-asserted-by":"publisher","first-page":"5134","DOI":"10.1182\/blood-2018-99-119528","volume":"132","author":"Y Niu","year":"2018","unstructured":"Niu, Y., Wu, S. & Hu, S. IGFBP7 as a potential therapeutic target for AML. Blood 132, 5134 (2018).","journal-title":"Blood"},{"key":"2843_CR294","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.268","volume":"5","author":"HJ Verhagen","year":"2014","unstructured":"Verhagen, H. J. et al. IGFBP7 induces apoptosis of acute myeloid leukemia cells and synergizes with chemotherapy in suppression of leukemia cell survival. Cell Death Dis. 5, e1300 (2014).","journal-title":"Cell Death Dis."},{"key":"2843_CR295","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1016\/j.celrep.2018.11.062","volume":"25","author":"H Verhagen","year":"2018","unstructured":"Verhagen, H. et al. IGFBP7 induces differentiation and loss of survival of human acute myeloid leukemia stem cells without affecting normal hematopoiesis. Cell Rep. 25, 3021\u20133035.e3025 (2018).","journal-title":"Cell Rep."},{"key":"2843_CR296","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3747\/co.23.2669","volume":"23","author":"S Fu","year":"2016","unstructured":"Fu, S. et al. Expression and clinical significance of insulin-like growth factor 1 in lung cancer tissues and perioperative circulation from patients with non-small-cell lung cancer. Curr. Oncol. 23, 12\u201319 (2016).","journal-title":"Curr. Oncol."},{"key":"2843_CR297","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.cllc.2013.12.006","volume":"15","author":"J-S Kim","year":"2014","unstructured":"Kim, J.-S. et al. Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with non\u2013small-cell lung cancer. Clin. Lung Cancer 15, 213\u2013221 (2014).","journal-title":"Clin. Lung Cancer"},{"key":"2843_CR298","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.21873\/anticanres.13578","volume":"39","author":"I Kotsantis","year":"2019","unstructured":"Kotsantis, I. et al. Prognostic significance of IGF-1 Signalling pathway in patients with advanced non-small cell lung cancer. Anticancer Res. 39, 4185\u20134190 (2019).","journal-title":"Anticancer Res."},{"key":"2843_CR299","first-page":"6694","volume":"7","author":"S Zhao","year":"2014","unstructured":"Zhao, S. et al. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in non-small cell lung cancer patients: a meta-analysis. Int. J. Clin. Exp. Pathol. 7, 6694\u20136704 (2014).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"2843_CR300","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1159\/000480655","volume":"43","author":"J Zhao","year":"2017","unstructured":"Zhao, J. et al. The prognostic and clinicopathological significance of IGF-1R in NSCLC: a meta-analysis. Cell Physiol. Biochem. 43, 697\u2013704 (2017).","journal-title":"Cell Physiol. Biochem."},{"key":"2843_CR301","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.cllc.2011.10.006","volume":"13","author":"M Nakagawa","year":"2012","unstructured":"Nakagawa, M. et al. Clinical significance of IGF1R expression in non\u2013small-cell lung cancer. Clin. Lung Cancer 13, 136\u2013142 (2012).","journal-title":"Clin. Lung Cancer"},{"key":"2843_CR302","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.canlet.2020.04.013","volume":"485","author":"Z Zhao","year":"2020","unstructured":"Zhao, Z. et al. Insulin-like growth factor-1 receptor induces immunosuppression in lung cancer by upregulating B7-H4 expression through the MEK\/ERK signaling pathway. Cancer Lett. 485, 14\u201326 (2020).","journal-title":"Cancer Lett."},{"key":"2843_CR303","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1158\/1541-7786.MCR-19-0956","volume":"18","author":"T Manabe","year":"2020","unstructured":"Manabe, T. et al. IGF2 autocrine-mediated IGF1R activation is a clinically relevant mechanism of osimertinib resistance in lung cancer. Mol. Cancer Res. 18, 549\u2013559 (2020).","journal-title":"Mol. Cancer Res."},{"key":"2843_CR304","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1159\/000366361","volume":"34","author":"Z Tian","year":"2014","unstructured":"Tian, Z. et al. IGF2R expression is associated with the chemotherapy response and prognosis of patients with advanced NSCLC. Cell Physiol. Biochem. 34, 1578\u20131588 (2014).","journal-title":"Cell Physiol. Biochem."},{"key":"2843_CR305","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06843-y","volume":"15","author":"H Lu","year":"2024","unstructured":"Lu, H. et al. IGFBP2\/ITGA5 promotes gefitinib resistance via activating STAT3\/CXCL1 axis in non-small cell lung cancer. Cell Death Dis. 15, 447 (2024).","journal-title":"Cell Death Dis."},{"key":"2843_CR306","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/onc.2009.454","volume":"29","author":"I Ibanez de Caceres","year":"2010","unstructured":"Ibanez de Caceres, I. et al. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer. Oncogene 29, 1681\u20131690 (2010).","journal-title":"Oncogene"},{"key":"2843_CR307","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/onc.2012.146","volume":"32","author":"M Cort\u00e9s-Sempere","year":"2013","unstructured":"Cort\u00e9s-Sempere, M. et al. IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR\/Akt pathway in non-small cell lung cancer. Oncogene 32, 1274\u20131283 (2013).","journal-title":"Oncogene"},{"key":"2843_CR308","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3390\/ijms19051479","volume":"19","author":"X Fan","year":"2018","unstructured":"Fan, X. et al. B-Myb mediates proliferation and migration of non-small-cell lung cancer via suppressing IGFBP3. Int. J. Mol. Sci. 19, 1479 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"2843_CR309","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41392-024-02075-w","volume":"10","author":"J Zheng","year":"2025","unstructured":"Zheng, J. et al. Hepatocellular carcinoma: signaling pathways and therapeutic advances. Signal Transduct. Target Ther. 10, 35 (2025).","journal-title":"Signal Transduct. Target Ther."},{"key":"2843_CR310","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s12026-025-09620-x","volume":"73","author":"E Wang","year":"2025","unstructured":"Wang, E. et al. HBx\/WDR5 enhances IGF-1 transcription in hepatocellular carcinoma cells and promotes recruitment, infiltration, and activity of Treg cells. Immunol. Res. 73, 69 (2025).","journal-title":"Immunol. Res."},{"key":"2843_CR311","doi-asserted-by":"publisher","DOI":"10.1016\/j.gassur.2025.102275","volume":"30","author":"J Eid","year":"2026","unstructured":"Eid, J. et al. Evaluating the role of preoperative serum insulin-like growth factor 1 as a predictor of survival and recurrence for patients with resectable hepatocellular carcinoma. J. Gastrointest. Surg. 30, 102275 (2026).","journal-title":"J. Gastrointest. Surg."},{"key":"2843_CR312","volume":"50","author":"AA Mohamed","year":"2025","unstructured":"Mohamed, A. A. et al. The prognostic utility of IGF-1 in hepatocellular carcinoma treated with stereotactic body radiotherapy. Clin. Transl. Radiat. Oncol. 50, 100887 (2025).","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"2843_CR313","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10561-7","volume":"23","author":"W Cai","year":"2023","unstructured":"Cai, W. et al. IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K\/akt and RAS\/raf\/ERK signaling pathways. BMC Cancer 23, 87 (2023).","journal-title":"BMC Cancer"},{"key":"2843_CR314","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1136\/jclinpath-2016-203998","volume":"70","author":"SB Lin","year":"2017","unstructured":"Lin, S. B. et al. Expression of GRK2 and IGF1R in hepatocellular carcinoma: clinicopathological and prognostic significance. J. Clin. Pathol. 70, 754\u2013759 (2017).","journal-title":"J. Clin. Pathol."},{"key":"2843_CR315","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.7150\/thno.65775","volume":"12","author":"M Xie","year":"2022","unstructured":"Xie, M. et al. Overexpression of BACH1 mediated by IGF2 facilitates hepatocellular carcinoma growth and metastasis via IGF1R and PTK2. Theranostics 12, 1097 (2022).","journal-title":"Theranostics"},{"key":"2843_CR316","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/cac2.12411","volume":"43","author":"H Suzuki","year":"2023","unstructured":"Suzuki, H. et al. Tumor-derived insulin-like growth factor-binding protein-1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors. Cancer Commun. 43, 415\u2013434 (2023).","journal-title":"Cancer Commun."},{"key":"2843_CR317","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.dld.2019.10.008","volume":"52","author":"Q Guo","year":"2020","unstructured":"Guo, Q. et al. IGFBP2 upregulates ZEB1 expression and promotes hepatocellular carcinoma progression through NF-\u03baB signaling pathway. Digest. Liver Dis. 52, 573\u2013581 (2020).","journal-title":"Digest. Liver Dis."},{"key":"2843_CR318","doi-asserted-by":"publisher","DOI":"10.1186\/s13027-023-00543-6","volume":"18","author":"X Chen","year":"2023","unstructured":"Chen, X. et al. IGFBP2 drives epithelial-mesenchymal transition in hepatocellular carcinoma via activating the Wnt\/\u03b2-catenin pathway. Infect. Agent Cancer 18, 73 (2023).","journal-title":"Infect. Agent Cancer"},{"key":"2843_CR319","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/tox.24177","volume":"40","author":"S Chen","year":"2025","unstructured":"Chen, S. et al. Deciphering m6A signatures in hepatocellular carcinoma: Single-cell insights, immune landscape, and the protective role of IGFBP3. Environ. Toxicol. 40, 367\u2013383 (2025).","journal-title":"Environ. Toxicol."},{"key":"2843_CR320","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3892\/ijo.2024.5710","volume":"66","author":"Y Sun","year":"2025","unstructured":"Sun, Y. et al. MYBBP1A\u2011mediated IGFBP4 promoter methylation promotes epithelial\u2011mesenchymal transition and metastasis through activation of NOTCH pathway in liver cancer. Int. J. Oncol. 66, 4 (2025).","journal-title":"Int. J. Oncol."},{"key":"2843_CR321","doi-asserted-by":"publisher","first-page":"6693","DOI":"10.1158\/1078-0432.CCR-10-2774","volume":"17","author":"D Chen","year":"2011","unstructured":"Chen, D. et al. Insulin-like growth factor-binding protein-7 functions as a potential tumor suppressor in hepatocellular carcinoma. Clin. Cancer Res. 17, 6693\u20136701 (2011).","journal-title":"Clin. Cancer Res."},{"key":"2843_CR322","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.612385","volume":"10","author":"E Tirr\u00f2","year":"2020","unstructured":"Tirr\u00f2, E. et al. Prognostic and therapeutic roles of the insulin growth factor system in glioblastoma. Front. Oncol. 10, 612385 (2020).","journal-title":"Front. Oncol."},{"key":"2843_CR323","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-018-0273-7","volume":"16","author":"CR Oliva","year":"2018","unstructured":"Oliva, C. R. et al. IGFBP6 controls the expansion of chemoresistant glioblastoma through paracrine IGF2\/IGF-1R signaling. Cell Commun. Signal. 16, 61 (2018).","journal-title":"Cell Commun. Signal."},{"key":"2843_CR324","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/bjc.2015.242","volume":"113","author":"C Maris","year":"2015","unstructured":"Maris, C. et al. IGF-IR: a new prognostic biomarker for human glioblastoma. Br. J. Cancer 113, 729\u2013737 (2015).","journal-title":"Br. J. Cancer"},{"key":"2843_CR325","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1158\/1055-9965.EPI-09-1213","volume":"19","author":"V Santosh","year":"2010","unstructured":"Santosh, V. et al. Grade-specific expression of insulin-like growth factor-binding proteins-2, -3, and -5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma. Cancer Epidemiol. Biomark. Prev. 19, 1399\u20131408 (2010).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"2843_CR326","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s11060-013-1324-y","volume":"116","author":"VR Praveen Kumar","year":"2014","unstructured":"Praveen Kumar, V. R. et al. Insulin like growth factor binding protein 4 promotes GBM progression and regulates key factors involved in EMT and invasion. J. Neurooncol. 116, 455\u2013464 (2014).","journal-title":"J. Neurooncol."},{"key":"2843_CR327","doi-asserted-by":"publisher","DOI":"10.1186\/s13008-020-00061-6","volume":"15","author":"C Dong","year":"2020","unstructured":"Dong, C., Zhang, J., Fang, S. & Liu, F. IGFBP5 increases cell invasion and inhibits cell proliferation by EMT and Akt signaling pathway in Glioblastoma multiforme cells. Cell Div. 15, 4 (2020).","journal-title":"Cell Div."},{"key":"2843_CR328","doi-asserted-by":"publisher","first-page":"232","DOI":"10.7150\/jca.87733","volume":"15","author":"J Lin","year":"2024","unstructured":"Lin, J. et al. IGFBP5, as a prognostic indicator promotes tumor progression and correlates with immune microenvironment in glioma. J. Cancer 15, 232\u2013250 (2024).","journal-title":"J. Cancer"},{"key":"2843_CR329","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.tem.2007.03.004","volume":"18","author":"RG Rosenfeld","year":"2007","unstructured":"Rosenfeld, R. G. et al. Defects in growth hormone receptor signaling. Trends Endocrinol. Metab. TEM 18, 134\u2013141 (2007).","journal-title":"Trends Endocrinol. Metab. TEM"},{"key":"2843_CR330","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55761-2","volume":"16","author":"KA Kentistou","year":"2025","unstructured":"Kentistou, K. A. et al. Rare variant associations with birth weight identify genes involved in adipose tissue regulation, placental function and insulin-like growth factor signalling. Nat. Commun. 16, 648 (2025).","journal-title":"Nat. Commun."},{"key":"2843_CR331","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41421-022-00502-2","volume":"8","author":"Q Zhong","year":"2022","unstructured":"Zhong, Q. et al. Structural insights into the covalent regulation of PAPP-A activity by proMBP and STC2. Cell Discov. 8, 137 (2022).","journal-title":"Cell Discov."},{"key":"2843_CR332","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53820-2","volume":"16","author":"L Guang","year":"2025","unstructured":"Guang, L. et al. An obesogenic FTO allele causes accelerated development, growth and insulin resistance in human skeletal muscle cells. Nat. Commun. 16, 1645 (2025).","journal-title":"Nat. Commun."},{"key":"2843_CR333","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1210\/er.2008-0047","volume":"30","author":"A Belfiore","year":"2009","unstructured":"Belfiore, A. et al. Insulin receptor isoforms and insulin receptor\/insulin-like growth factor receptor hybrids in physiology and disease. Endocr. Rev. 30, 586\u2013623 (2009).","journal-title":"Endocr. Rev."},{"key":"2843_CR334","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/jbmr.281","volume":"26","author":"C Ohlsson","year":"2011","unstructured":"Ohlsson, C. et al. Older men with low serum IGF-1 have an increased risk of incident fractures: the MrOS Sweden study. J. Bone Min. Res. 26, 865\u2013872 (2011).","journal-title":"J. Bone Min. Res."},{"key":"2843_CR335","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/j.1745-7270.2006.00218.x","volume":"38","author":"H Tian","year":"2006","unstructured":"Tian, H. & Stogiannidis, I. Up-regulation of cartilage oligomeric matrix protein gene expression by insulin-like growth factor-I revealed by real-time reverse transcription-polymerase chain reaction. Acta Biochim. Biophys. Sin. 38, 677\u2013682 (2006).","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"2843_CR336","first-page":"703","volume":"106","author":"MB Ranke","year":"2009","unstructured":"Ranke, M. B., Wolfle, J., Schnabel, D. & Bettendorf, M. Treatment of dwarfism with recombinant human insulin-like growth factor-1. Dtsch Arztebl Int 106, 703\u2013709 (2009).","journal-title":"Dtsch Arztebl Int"},{"key":"2843_CR337","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41574-022-00649-8","volume":"18","author":"G Mazziotti","year":"2022","unstructured":"Mazziotti, G., Lania, A. G. & Canalis, E. Skeletal disorders associated with the growth hormone-insulin-like growth factor 1 axis. Nat. Rev. Endocrinol. 18, 353\u2013365 (2022).","journal-title":"Nat. Rev. Endocrinol."},{"key":"2843_CR338","doi-asserted-by":"publisher","first-page":"101318","DOI":"10.1016\/j.ghir.2020.101318","volume":"52","author":"GM Bright","year":"2020","unstructured":"Bright, G. M. & Fierro-Renoy, J. F. A rationale for the treatment of short stature in children with the combination of recombinant human growth hormone (rhGH) and recombinant human insulin-like growth factor-I (rhIGF-I). Growth Horm. IGF Res. 52, 101318 (2020).","journal-title":"Growth Horm. IGF Res."},{"key":"2843_CR339","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.1210\/jcem.84.12.6255","volume":"84","author":"Z Laron","year":"1999","unstructured":"Laron, Z. The essential role of IGF-I: lessons from the long-term study and treatment of children and adults with Laron syndrome. J. Clin. Endocrinol. Metab. 84, 4397\u20134404 (1999).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2843_CR340","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1002\/jbmr.1847","volume":"28","author":"JG Logan","year":"2013","unstructured":"Logan, J. G. et al. Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis. J. Bone Min. Res. 28, 1229\u20131242 (2013).","journal-title":"J. Bone Min. Res."},{"key":"2843_CR341","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3389\/fendo.2019.00316","volume":"10","author":"V Garla","year":"2019","unstructured":"Garla, V. et al. Non-islet cell hypoglycemia: case series and review of the literature. Front. Endocrinol. 10, 316 (2019).","journal-title":"Front. Endocrinol."},{"key":"2843_CR342","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.celrep.2015.04.037","volume":"11","author":"BT O\u2019Neill","year":"2015","unstructured":"O\u2019Neill, B. T. et al. Differential role of insulin\/IGF-1 receptor signaling in muscle growth and glucose homeostasis. Cell Rep. 11, 1220\u20131235 (2015).","journal-title":"Cell Rep."},{"key":"2843_CR343","first-page":"None","volume":"2","author":"EJ Gardner","year":"2022","unstructured":"Gardner, E. J. et al. Damaging missense variants in IGF1R implicate a role for IGF-1 resistance in the etiology of type 2 diabetes. Cell Genom. 2, None (2022).","journal-title":"Cell Genom."},{"key":"2843_CR344","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1530\/EC-17-0038","volume":"6","author":"R Solomon-Zemler","year":"2017","unstructured":"Solomon-Zemler, R. et al. A novel heterozygous IGF-1 receptor mutation associated with hypoglycemia. Endocr. Connect 6, 395\u2013403 (2017).","journal-title":"Endocr. Connect"},{"key":"2843_CR345","doi-asserted-by":"publisher","first-page":"9556","DOI":"10.3390\/ijms24119556","volume":"24","author":"S Al-Samerria","year":"2023","unstructured":"Al-Samerria, S. & Radovick, S. Exploring the therapeutic potential of targeting GH and IGF-1 in the management of obesity: insights from the interplay between these hormones and metabolism. Int. J. Mol. Sci. 24, 9556 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2843_CR346","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40798-024-00697-6","volume":"10","author":"FG Di Girolamo","year":"2024","unstructured":"Di Girolamo, F. G. et al. Metabolic consequences of anabolic steroids, insulin, and growth hormone abuse in recreational bodybuilders: implications for the World Anti-Doping Agency passport. Sports Med. Open 10, 28 (2024).","journal-title":"Sports Med. Open"},{"key":"2843_CR347","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1900\/RDS.2020.16.24","volume":"16","author":"B Biadgo","year":"2020","unstructured":"Biadgo, B., Tamir, W. & Ambachew, S. Insulin-like growth factor and its therapeutic potential for diabetes complications - mechanisms and metabolic links: a review. Rev. Diabet. Stud. 16, 24\u201334 (2020).","journal-title":"Rev. Diabet. Stud."},{"key":"2843_CR348","first-page":"73","volume":"3","author":"JH Bae","year":"2013","unstructured":"Bae, J. H., Song, D. K. & Im, S. S. Regulation of IGFBP-1 in metabolic diseases. J. Lifestyle Med. 3, 73\u201379 (2013).","journal-title":"J. Lifestyle Med."},{"key":"2843_CR349","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1651-2227.1991.tb17983.x","volume":"372","author":"RC Baxter","year":"1991","unstructured":"Baxter, R. C. Insulin-like growth factor (IGF) binding proteins: the role of serum IGFBPs in regulating IGF availability. Acta Paediatr. Scand. Suppl. 372, 107\u2013114 (1991).","journal-title":"Acta Paediatr. Scand. Suppl."},{"key":"2843_CR350","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3389\/fendo.2018.00499","volume":"9","author":"H Ding","year":"2018","unstructured":"Ding, H. & Wu, T. Insulin-like growth factor binding proteins in autoimmune diseases. Front. Endocrinol. 9, 499 (2018).","journal-title":"Front. Endocrinol."},{"key":"2843_CR351","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1142644","volume":"14","author":"M Macvanin","year":"2023","unstructured":"Macvanin, M. et al. New insights on the cardiovascular effects of IGF-1. Front. Endocrinol. 14, 1142644 (2023).","journal-title":"Front. Endocrinol."},{"key":"2843_CR352","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.1091\/mbc.e07-03-0280","volume":"18","author":"KS Kim","year":"2007","unstructured":"Kim, K. S. et al. Induction of cellular senescence by insulin-like growth factor binding protein-5 through a p53-dependent mechanism. Mol. Biol. Cell 18, 4543\u20134552 (2007).","journal-title":"Mol. Biol. Cell"},{"key":"2843_CR353","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.5551\/jat.52993","volume":"27","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. IGFBP6 is downregulated in unstable carotid atherosclerotic plaques according to an integrated bioinformatics analysis and experimental verification. J. Atheroscler. Thromb. 27, 1068\u20131085 (2020).","journal-title":"J. Atheroscler. Thromb."},{"key":"2843_CR354","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrcardio.2014.28","volume":"11","author":"NG Frangogiannis","year":"2014","unstructured":"Frangogiannis, N. G. The inflammatory response in myocardial injury, repair, and remodelling. Nat. Rev. Cardiol. 11, 255\u2013265 (2014).","journal-title":"Nat. Rev. Cardiol."},{"key":"2843_CR355","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1210\/jc.2006-1631","volume":"92","author":"RC Kaplan","year":"2007","unstructured":"Kaplan, R. C. et al. Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke. J. Clin. Endocrinol. Metab. 92, 1319\u20131325 (2007).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2843_CR356","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.cyto.2015.06.015","volume":"76","author":"Y Zhang","year":"2015","unstructured":"Zhang, Y. et al. Extensive serum biomarker analysis in patients with ST segment elevation myocardial infarction (STEMI). Cytokine 76, 356\u2013362 (2015).","journal-title":"Cytokine"},{"key":"2843_CR357","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.132268","volume":"411","author":"Q Zhu","year":"2024","unstructured":"Zhu, Q. et al. Serum IGFBP5 as a predictor of major adverse cardiac events in patients with acute myocardial infarction. Int. J. Cardiol. 411, 132268 (2024).","journal-title":"Int. J. Cardiol."},{"key":"2843_CR358","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1152\/physiol.00003.2024","volume":"39","author":"W-S Lee","year":"2024","unstructured":"Lee, W.-S., Abel, E. D. & Kim, J. New insights into IGF-1 signaling in the heart. Physiology 39, 302\u2013312 (2024).","journal-title":"Physiology"},{"key":"2843_CR359","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/ehf2.12590","volume":"7","author":"AA Konev","year":"2020","unstructured":"Konev, A. A. et al. CT-IGFBP-4 as a novel prognostic biomarker in acute heart failure. ESC Heart Fail 7, 434\u2013444 (2020).","journal-title":"ESC Heart Fail"},{"key":"2843_CR360","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12933-018-0710-3","volume":"17","author":"G Cediel","year":"2018","unstructured":"Cediel, G. et al. Prognostic value of the Stanniocalcin-2\/PAPP-A\/IGFBP-4 axis in ST-segment elevation myocardial infarction. Cardiovasc Diabetol. 17, 63 (2018).","journal-title":"Cardiovasc Diabetol."},{"key":"2843_CR361","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1210\/jc.2015-2196","volume":"100","author":"R Hjortebjerg","year":"2015","unstructured":"Hjortebjerg, R. et al. IGFBP-4 fragments as markers of cardiovascular mortality in type 1 diabetes patients with and without nephropathy. J. Clin. Endocrinol. Metab. 100, 3032\u20133040 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2843_CR362","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11064-010-0260-x","volume":"36","author":"H Zhang","year":"2011","unstructured":"Zhang, H. et al. IGF-1 reduces BACE-1 expression in PC12 cells via activation of PI3-K\/Akt and MAPK\/ERK1\/2 signaling pathways. Neurochem. Res. 36, 49\u201357 (2011).","journal-title":"Neurochem. Res."},{"key":"2843_CR363","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-015-0174-2","volume":"8","author":"K Watanabe","year":"2015","unstructured":"Watanabe, K. et al. The participation of insulin-like growth factor-binding protein 3 released by astrocytes in the pathology of Alzheimer\u2019s disease. Mol. Brain 8, 82 (2015).","journal-title":"Mol. Brain"},{"key":"2843_CR364","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1111\/cns.14160","volume":"29","author":"GS Fitzgerald","year":"2023","unstructured":"Fitzgerald, G. S., Chuchta, T. G. & McNay, E. C. Insulin-like growth factor-2 is a promising candidate for the treatment and prevention of Alzheimer\u2019s disease. CNS Neurosci. Ther. 29, 1449\u20131469 (2023).","journal-title":"CNS Neurosci. Ther."},{"key":"2843_CR365","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3389\/fnins.2018.00476","volume":"12","author":"LW Bonham","year":"2018","unstructured":"Bonham, L. W. et al. Insulin-like growth factor binding protein 2 is associated with biomarkers of Alzheimer\u2019s disease pathology and shows differential expression in transgenic mice. Front. Neurosci. 12, 476 (2018).","journal-title":"Front. Neurosci."},{"key":"2843_CR366","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4103\/abr.abr_23_23","volume":"14","author":"N Naseri","year":"2025","unstructured":"Naseri, N. & Mofid, M. R. Role of IGFBP-3 in human diseases relying on different cell signaling pathways. Adv. Biomed. Res. 14, 15 (2025).","journal-title":"Adv. Biomed. Res."},{"key":"2843_CR367","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1169620","volume":"15","author":"B Jin","year":"2023","unstructured":"Jin, B. et al. Identification of diagnostic biomarkers in Alzheimer\u2019s disease by integrated bioinformatic analysis and machine learning strategies. Front. Aging Neurosci. 15, 1169620 (2023).","journal-title":"Front. Aging Neurosci."},{"key":"2843_CR368","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s10072-024-07835-8","volume":"46","author":"L Gu","year":"2025","unstructured":"Gu, L. et al. Association between serum IGF\u20111 levels and non-motor symptoms in Parkinson\u2019s disease. Neurol. Sci. 46, 1201\u20131206 (2025).","journal-title":"Neurol. Sci."},{"key":"2843_CR369","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.3233\/JPD-223363","volume":"12","author":"C Coleman","year":"2022","unstructured":"Coleman, C. & Martin, I. Unraveling Parkinson\u2019s disease neurodegeneration: does aging hold the clues? J. Parkinsons Dis. 12, 2321\u20132338 (2022).","journal-title":"J. Parkinsons Dis."},{"key":"2843_CR370","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1371\/journal.pbio.0060254","volume":"6","author":"L Kappeler","year":"2008","unstructured":"Kappeler, L. et al. Brain IGF-1 receptors control mammalian growth and lifespan through a neuroendocrine mechanism. PLoS Biol. 6, e254 (2008).","journal-title":"PLoS Biol."},{"key":"2843_CR371","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/acel.12365","volume":"14","author":"Z Chaker","year":"2015","unstructured":"Chaker, Z., A\u00efd, S., Berry, H. & Holzenberger, M. Suppression of IGF-I signals in neural stem cells enhances neurogenesis and olfactory function during aging. Aging Cell 14, 847\u2013856 (2015).","journal-title":"Aging Cell"},{"key":"2843_CR372","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.cmet.2023.12.007","volume":"36","author":"L Guarente","year":"2024","unstructured":"Guarente, L., Sinclair, D. A. & Kroemer, G. Human trials exploring anti-aging medicines. Cell Metab. 36, 354\u2013376 (2024).","journal-title":"Cell Metab."},{"key":"2843_CR373","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02223-0","volume":"18","author":"I Castilla-Cort\u00e1zar","year":"2020","unstructured":"Castilla-Cort\u00e1zar, I. et al. Is insulin-like growth factor-1 involved in Parkinson\u2019s disease development? J. Transl. Med. 18, 70 (2020).","journal-title":"J. Transl. Med."},{"key":"2843_CR374","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s12035-014-8735-4","volume":"51","author":"L Naia","year":"2015","unstructured":"Naia, L. et al. Activation of IGF-1 and insulin signaling pathways ameliorate mitochondrial function and energy metabolism in Huntington\u2019s Disease human lymphoblasts. Mol. Neurobiol. 51, 331\u2013348 (2015).","journal-title":"Mol. Neurobiol."},{"key":"2843_CR375","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13578-025-01452-4","volume":"15","author":"YS Tung","year":"2025","unstructured":"Tung, Y. S. et al. Insulin-like growth factor 2 reduces Huntington\u2019s disease aggregates via AKT and NF-\u03baB signaling in huntington\u2019s disease. Cell Biosci. 15, 109 (2025).","journal-title":"Cell Biosci."},{"key":"2843_CR376","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.autrev.2014.01.013","volume":"13","author":"F Menconi","year":"2014","unstructured":"Menconi, F., Marcocci, C. & Marin\u00f2, M. Diagnosis and classification of Graves\u2019 disease. Autoimmun. Rev. 13, 398\u2013402 (2014).","journal-title":"Autoimmun. Rev."},{"key":"2843_CR377","doi-asserted-by":"publisher","first-page":"5768","DOI":"10.4049\/jimmunol.181.8.5768","volume":"181","author":"RS Douglas","year":"2008","unstructured":"Douglas, R. S. et al. B cells from patients with Graves\u2019 disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J. Immunol. 181, 5768\u20135774 (2008).","journal-title":"J. Immunol."},{"key":"2843_CR378","doi-asserted-by":"publisher","first-page":"E153","DOI":"10.1210\/jc.2013-3106","volume":"99","author":"L Batey","year":"2014","unstructured":"Batey, L. et al. A novel deletion of IGF1 in a patient with idiopathic short stature provides insight Into IGF1 haploinsufficiency. J. Clin. Endocrinol. Metab. 99, E153\u2013E159 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2843_CR379","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1210\/er.2018-00066","volume":"40","author":"TJ Smith","year":"2019","unstructured":"Smith, T. J. & Janssen, J. Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy. Endocr. Rev. 40, 236\u2013267 (2019).","journal-title":"Endocr. Rev."},{"key":"2843_CR380","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1210\/jc.2014-3566","volume":"100","author":"CC Krieger","year":"2015","unstructured":"Krieger, C. C. et al. Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves\u2019 disease immunoglobins. J. Clin. Endocrinol. Metab. 100, 1071\u20131077 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2843_CR381","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3109\/08916934.2014.976631","volume":"48","author":"S Suzuki","year":"2015","unstructured":"Suzuki, S. et al. Inhibition of the insulin-like growth factor system is a potential therapy for rheumatoid arthritis. Autoimmunity 48, 251\u2013258 (2015).","journal-title":"Autoimmunity"},{"key":"2843_CR382","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cca.2005.11.015","volume":"367","author":"SD Lee","year":"2006","unstructured":"Lee, S. D. et al. Serum insulin-like growth factor-axis and matrix metalloproteinases in patients with rheumatic arthritis or rheumatic heart disease. Clin. Chim. Acta 367, 62\u201368 (2006).","journal-title":"Clin. Chim. Acta"},{"key":"2843_CR383","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1002\/art.30527","volume":"63","author":"EA Bostr\u00f6m","year":"2011","unstructured":"Bostr\u00f6m, E. A. et al. Resistin and insulin\/insulin-like growth factor signaling in rheumatoid arthritis. Arthritis Rheum. 63, 2894\u20132904 (2011).","journal-title":"Arthritis Rheum."},{"key":"2843_CR384","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/art.27269","volume":"62","author":"H Marotte","year":"2010","unstructured":"Marotte, H., Ahmed, S., Ruth, J. H. & Koch, A. E. Blocking ERK-1\/2 reduces tumor necrosis factor alpha-induced interleukin-18 bioactivity in rheumatoid arthritis synovial fibroblasts by induction of interleukin-18 binding protein A. Arthritis Rheum. 62, 722\u2013731 (2010).","journal-title":"Arthritis Rheum."},{"key":"2843_CR385","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/cei.12374","volume":"177","author":"MC Lu","year":"2014","unstructured":"Lu, M. C. et al. Increased miR-223 expression in T cells from patients with rheumatoid arthritis leads to decreased insulin-like growth factor-1-mediated interleukin-10 production. Clin. Exp. Immunol. 177, 641\u2013651 (2014).","journal-title":"Clin. Exp. Immunol."},{"key":"2843_CR386","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.3390\/ijms25084442","volume":"25","author":"DS Chae","year":"2024","unstructured":"Chae, D. S., Han, S. & Kim, S. W. IGF-1 genome-edited human MSCs exhibit robust anti-arthritogenicity in collagen-induced arthritis. Int. J. Mol. Sci. 25, 4442 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2843_CR387","doi-asserted-by":"publisher","DOI":"10.1186\/1750-9378-9-27","volume":"9","author":"C Pivonello","year":"2014","unstructured":"Pivonello, C. et al. The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets. Infect. Agent. Cancer 9, 27 (2014).","journal-title":"Infect. Agent. Cancer"},{"key":"2843_CR388","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.3899\/jrheum.150280","volume":"42","author":"JF Baker","year":"2015","unstructured":"Baker, J. F. et al. Insulin-like growth factor 1 and adiponectin and associations with muscle deficits, disease characteristics, and treatments in rheumatoid arthritis. J. Rheumatol. 42, 2038\u20132045 (2015).","journal-title":"J. Rheumatol."},{"key":"2843_CR389","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/cei.13080","volume":"192","author":"J Li","year":"2018","unstructured":"Li, J. et al. TXNDC5 contributes to rheumatoid arthritis by down-regulating IGFBP1 expression. Clin. Exp. Immunol. 192, 82\u201394 (2018).","journal-title":"Clin. Exp. Immunol."},{"key":"2843_CR390","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jaut.2015.08.004","volume":"64","author":"Y Ghodke-Puranik","year":"2015","unstructured":"Ghodke-Puranik, Y. & Niewold, T. B. Immunogenetics of systemic lupus erythematosus: a comprehensive review. J. Autoimmun. 64, 125\u2013136 (2015).","journal-title":"J. Autoimmun."},{"key":"2843_CR391","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1177\/0961203318756288","volume":"27","author":"J Waldron","year":"2018","unstructured":"Waldron, J., Raymond, W., Ostli-Eilertsen, G. & Nossent, J. Insulin-like growth factor-1 (IGF1) in systemic lupus erythematosus: relation to disease activity, organ damage and immunological findings. Lupus 27, 963\u2013970 (2018).","journal-title":"Lupus"},{"key":"2843_CR392","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/acr.22835","volume":"68","author":"CC Mok","year":"2016","unstructured":"Mok, C. C., Ding, H. H., Kharboutli, M. & Mohan, C. Axl, ferritin, insulin-like growth factor binding protein 2, and tumor necrosis factor receptor type II as biomarkers in systemic lupus erythematosus. Arthritis Care Res. 68, 1303\u20131309 (2016).","journal-title":"Arthritis Care Res."},{"key":"2843_CR393","doi-asserted-by":"publisher","first-page":"9596","DOI":"10.3390\/ijms26199596","volume":"26","author":"FA Mendoza","year":"2025","unstructured":"Mendoza, F. A., Piera-Velazquez, S. & Jimenez, S. A. Role of growth factors in the pathogenesis of systemic-sclerosis-associated fibrosis. Int J. Mol. Sci. 26, 9596 (2025).","journal-title":"Int J. Mol. Sci."},{"key":"2843_CR394","volume":"2018","author":"Z Wang","year":"2018","unstructured":"Wang, Z. et al. Insulin-Like Growth Factor-1 Signaling in Lung Development and Inflammatory Lung Diseases. Biomed. Res Int. 2018, 6057589 (2018).","journal-title":"Biomed. Res Int."},{"key":"2843_CR395","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.3390\/biom12111557","volume":"12","author":"Y Zhu","year":"2022","unstructured":"Zhu, Y. et al. Insulin-like Growth Factor-2 (IGF-2) in fibrosis. Biomolecules 12, 1557 (2022).","journal-title":"Biomolecules"},{"key":"2843_CR396","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1034\/j.1601-0825.2003.02898.x","volume":"9","author":"J Katz","year":"2003","unstructured":"Katz, J. et al. IGF-1 and insulin receptor expression in the minor salivary gland tissues of Sj\u00f6gren\u2019s syndrome and mucoceles\u2013immunohistochemical study. Oral. Dis. 9, 7\u201313 (2003).","journal-title":"Oral. Dis."},{"key":"2843_CR397","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1601-0825.2000.tb00318.x","volume":"6","author":"AK Markopoulos","year":"2000","unstructured":"Markopoulos, A. K., Poulopoulos, A. K., Kayavis, I. & Papanayotou, P. Immunohistochemical detection of insulin-like growth factor-I in the labial salivary glands of patients with Sj\u00f6gren\u2019s syndrome. Oral. Dis. 6, 31\u201334 (2000).","journal-title":"Oral. Dis."},{"key":"2843_CR398","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/gene.2009.20","volume":"10","author":"ES Emamian","year":"2009","unstructured":"Emamian, E. S. et al. Peripheral blood gene expression profiling in Sj\u00f6gren\u2019s syndrome. Genes Immun. 10, 285\u2013296 (2009).","journal-title":"Genes Immun."},{"key":"2843_CR399","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.3390\/jcm10173960","volume":"10","author":"C Skarlis","year":"2021","unstructured":"Skarlis, C. et al. +3179G\/A insulin-like growth factor-1 receptor polymorphism: a novel susceptibility contributor in anti-Ro\/SSA positive patients with sj\u00f6gren\u2019s syndrome: potential clinical and pathogenetic implications. J. Clin. Med. 10, 3960 (2021).","journal-title":"J. Clin. Med."},{"key":"2843_CR400","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-5-301","volume":"5","author":"OR Cotta","year":"2011","unstructured":"Cotta, O. R. et al. Primary growth hormone insensitivity (Laron syndrome) and acquired hypothyroidism: a case report. J. Med. Case Rep. 5, 301 (2011).","journal-title":"J. Med. Case Rep."},{"key":"2843_CR401","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/cen.12555","volume":"82","author":"M Juanes","year":"2015","unstructured":"Juanes, M. et al. Three novel IGF1R mutations in microcephalic patients with prenatal and postnatal growth impairment. Clin. Endocrinol. 82, 704\u2013711 (2015).","journal-title":"Clin. Endocrinol."},{"key":"2843_CR402","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1530\/EJE-20-1463","volume":"185","author":"W Staels","year":"2021","unstructured":"Staels, W. et al. IGF1 haploinsufficiency in children with short stature: a case series. Eur. J. Endocrinol. 185, 323\u2013332 (2021).","journal-title":"Eur. J. Endocrinol."},{"key":"2843_CR403","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3389\/fnins.2016.00450","volume":"10","author":"C Vahdatpour","year":"2016","unstructured":"Vahdatpour, C., Dyer, A. H. & Tropea, D. Insulin-like growth factor 1 and related compounds in the treatment of childhood-onset neurodevelopmental disorders. Front. Neurosci. 10, 450 (2016).","journal-title":"Front. Neurosci."},{"key":"2843_CR404","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/ijms20010067","volume":"20","author":"B Brigant","year":"2018","unstructured":"Brigant, B., Metzinger-Le Meuth, V., Rochette, J. & Metzinger, L. TRIMming down to TRIM37: relevance to inflammation, cardiovascular disorders, and cancer in mulibrey nanism. Int. J. Mol. Sci. 20, 67 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"2843_CR405","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1056\/NEJMoa013100","volume":"350","author":"HM Domen\u00e9","year":"2004","unstructured":"Domen\u00e9, H. M. et al. Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene. N. Engl. J. Med. 350, 570\u2013577 (2004).","journal-title":"N. Engl. J. Med."},{"key":"2843_CR406","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121244","volume":"280","author":"PJ Hanwright","year":"2022","unstructured":"Hanwright, P. J. et al. Sustained IGF-1 delivery ameliorates effects of chronic denervation and improves functional recovery after peripheral nerve injury and repair. Biomaterials 280, 121244 (2022).","journal-title":"Biomaterials"},{"key":"2843_CR407","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2024.101403","volume":"30","author":"T Wan","year":"2025","unstructured":"Wan, T. et al. Biomimetic ECM nerve guidance conduit with dynamic 3D interconnected porous network and sustained IGF-1 delivery for enhanced peripheral nerve regeneration and immune modulation. Mater. Today Biol. 30, 101403 (2025).","journal-title":"Mater. Today Biol."},{"key":"2843_CR408","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1161\/HYPERTENSIONAHA.124.24341","volume":"82","author":"X Xu","year":"2025","unstructured":"Xu, X. et al. IGF-1 provides protective role in arteriosclerotic cerebral small vessel disease. Hypertension 82, 1137\u20131150 (2025).","journal-title":"Hypertension"},{"key":"2843_CR409","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s00192-025-06174-2","volume":"36","author":"H Xu","year":"2025","unstructured":"Xu, H. et al. Expressions of IGF-1, pAKT, and pS6 in uterosacral ligaments of patients with pelvic organ prolapse. Int. Urogynecol. J. 36, 1523\u20131531 (2025).","journal-title":"Int. Urogynecol. J."},{"key":"2843_CR410","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11102-024-01479-9","volume":"28","author":"S Chiloiro","year":"2024","unstructured":"Chiloiro, S. et al. IGF-I levels during standard Lanreotide dose predicts biochemical outcome of high-frequency regimen in acromegaly. Pituitary 28, 7 (2024).","journal-title":"Pituitary"},{"key":"2843_CR411","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1089\/neur.2025.0009","volume":"6","author":"J Weppner","year":"2025","unstructured":"Weppner, J. et al. IGF-1 as a biomarker for symptom severity in adult traumatic brain injury: evidence from an observational study. Neurotrauma Rep. 6, 345\u2013354 (2025).","journal-title":"Neurotrauma Rep."},{"key":"2843_CR412","doi-asserted-by":"publisher","first-page":"696","DOI":"10.2337\/diab.42.5.696","volume":"42","author":"H Kuzuya","year":"1993","unstructured":"Kuzuya, H. et al. Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes 42, 696\u2013705 (1993).","journal-title":"Diabetes"},{"key":"2843_CR413","doi-asserted-by":"publisher","first-page":"e142245","DOI":"10.1172\/JCI142245","volume":"131","author":"AM Angelidi","year":"2021","unstructured":"Angelidi, A. M., Filippaios, A. & Mantzoros, C. S. Severe insulin resistance syndromes. J. Clin. Invest 131, e142245 (2021).","journal-title":"J. Clin. Invest"},{"key":"2843_CR414","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-981-10-4304-8_12","volume":"1000","author":"KL Weeks","year":"2017","unstructured":"Weeks, K. L. et al. The IGF1-PI3K-Akt Signaling Pathway in Mediating Exercise-Induced Cardiac Hypertrophy and Protection. Adv. Exp. Med. Biol. 1000, 187\u2013210 (2017).","journal-title":"Adv. Exp. Med. Biol."},{"key":"2843_CR415","doi-asserted-by":"publisher","first-page":"6349","DOI":"10.1074\/jbc.M114.634154","volume":"290","author":"SM Jacobo","year":"2015","unstructured":"Jacobo, S. M. & Kazlauskas, A. Insulin-like growth factor 1 (IGF-1) stabilizes nascent blood vessels. J. Biol. Chem. 290, 6349\u20136360 (2015).","journal-title":"J. Biol. Chem."},{"key":"2843_CR416","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13287-019-1544-y","volume":"11","author":"M Lin","year":"2020","unstructured":"Lin, M. et al. IGF-1 enhances BMSC viability, migration, and anti-apoptosis in myocardial infarction via secreted frizzled-related protein 2 pathway. Stem Cell Res. Ther. 11, 22 (2020).","journal-title":"Stem Cell Res. Ther."},{"key":"2843_CR417","doi-asserted-by":"publisher","first-page":"4512","DOI":"10.3390\/ijms25084512","volume":"25","author":"MS Lewitt","year":"2024","unstructured":"Lewitt, M. S. & Boyd, G. W. Role of the Insulin-like Growth Factor System in Neurodegenerative Disease. Int J. Mol. Sci. 25, 4512 (2024).","journal-title":"Int J. Mol. Sci."},{"key":"2843_CR418","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2022.136575","volume":"776","author":"Y Wan","year":"2022","unstructured":"Wan, Y. et al. Role of IGF-1 in neuroinflammation and cognition deficits induced by sleep deprivation. Neurosci. Lett. 776, 136575 (2022).","journal-title":"Neurosci. Lett."},{"key":"2843_CR419","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115084","volume":"161","author":"T Zhu","year":"2025","unstructured":"Zhu, T. et al. Targeting insulin-like growth factor 1 signaling with Linsitinib to modulate fibroblast plasticity and attenuate pulmonary fibrosis. Int. Immunopharmacol. 161, 115084 (2025).","journal-title":"Int. Immunopharmacol."},{"key":"2843_CR420","first-page":"553","volume":"5","author":"D Fintini","year":"2009","unstructured":"Fintini, D., Brufani, C. & Cappa, M. Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency. Ther. Clin. Risk Manag. 5, 553\u2013559 (2009).","journal-title":"Ther. Clin. Risk Manag."},{"key":"2843_CR421","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/jnci\/djs258","volume":"104","author":"D Yee","year":"2012","unstructured":"Yee, D. Insulin-like growth factor receptor inhibitors: baby or the bathwater? J. Natl. Cancer Inst. 104, 975\u2013981 (2012).","journal-title":"J. Natl. Cancer Inst."},{"key":"2843_CR422","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1200\/JCO.2013.54.4932","volume":"32","author":"CJ Langer","year":"2014","unstructured":"Langer, C. J. et al. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 32, 2059\u20132066 (2014).","journal-title":"J. Clin. Oncol."},{"key":"2843_CR423","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1158\/1078-0432.CCR-12-0061","volume":"18","author":"A Naing","year":"2012","unstructured":"Naing, A. et al. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing\u2019s sarcoma family tumors. Clin. Cancer Res. 18, 2625\u20132631 (2012).","journal-title":"Clin. Cancer Res."},{"key":"2843_CR424","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1530\/ERC-12-0390","volume":"20","author":"JR Strosberg","year":"2013","unstructured":"Strosberg, J. R. et al. A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors. Endocr. Relat. Cancer 20, 383\u2013390 (2013).","journal-title":"Endocr. Relat. Cancer"},{"key":"2843_CR425","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1158\/1078-0432.CCR-11-3369","volume":"18","author":"LS Rosen","year":"2012","unstructured":"Rosen, L. S. et al. Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors. Clin. Cancer Res. 18, 3414\u20133427 (2012).","journal-title":"Clin. Cancer Res."},{"key":"2843_CR426","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00280-013-2240-8","volume":"72","author":"T Doi","year":"2013","unstructured":"Doi, T. et al. Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer. Cancer Chemother. Pharm. 72, 643\u2013652 (2013).","journal-title":"Cancer Chemother. Pharm."},{"key":"2843_CR427","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.annonc.2019.09.004","volume":"31","author":"M Kundranda","year":"2020","unstructured":"Kundranda, M. et al. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). Ann. Oncol. 31, 79\u201387 (2020).","journal-title":"Ann. Oncol."},{"key":"2843_CR428","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1002\/cncr.28728","volume":"120","author":"AS Pappo","year":"2014","unstructured":"Pappo, A. S. et al. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study. Cancer 120, 2448\u20132456 (2014).","journal-title":"Cancer"},{"key":"2843_CR429","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1634\/theoncologist.2016-0377","volume":"23","author":"G Vlahovic","year":"2018","unstructured":"Vlahovic, G. et al. A phase I trial of the IGF-1R antibody ganitumab (AMG 479) in combination with everolimus (RAD001) and panitumumab in patients with advanced cancer. Oncologist 23, 782\u2013790 (2018).","journal-title":"Oncologist"},{"key":"2843_CR430","doi-asserted-by":"publisher","first-page":"djv258","DOI":"10.1093\/jnci\/djv258","volume":"107","author":"F Sclafani","year":"2015","unstructured":"Sclafani, F. et al. A randomized phase II\/III study of dalotuzumab in combination with cetuximab and irinotecan in chemorefractory, KRAS wild-type, metastatic colorectal cancer. JNCI: J. Natl. Cancer Inst. 107, djv258 (2015).","journal-title":"JNCI: J. Natl. Cancer Inst."},{"key":"2843_CR431","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00280-013-2372-x","volume":"73","author":"D Mahadevan","year":"2014","unstructured":"Mahadevan, D. et al. Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. Cancer Chemother. Pharm. 73, 467\u2013473 (2014).","journal-title":"Cancer Chemother. Pharm."},{"key":"2843_CR432","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/annonc\/mdv027","volume":"26","author":"CS Fuchs","year":"2015","unstructured":"Fuchs, C. S. et al. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial. Ann. Oncol. 26, 921\u2013927 (2015).","journal-title":"Ann. Oncol."},{"key":"2843_CR433","doi-asserted-by":"publisher","first-page":"15705","DOI":"10.1021\/bi001516y","volume":"39","author":"G Blum","year":"2000","unstructured":"Blum, G., Gazit, A. & Levitzki, A. Substrate competitive inhibitors of IGF-1 receptor kinase. Biochemistry 39, 15705\u201315712 (2000).","journal-title":"Biochemistry"},{"key":"2843_CR434","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1158\/0008-5472.CAN-05-1107","volume":"66","author":"P Haluska","year":"2006","unstructured":"Haluska, P. et al. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I\/insulin receptor inhibitor, BMS-554417. Cancer Res. 66, 362\u2013371 (2006).","journal-title":"Cancer Res."},{"key":"2843_CR435","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1158\/1535-7163.MCT-09-0499","volume":"8","author":"JM Carboni","year":"2009","unstructured":"Carboni, J. M. et al. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R\/IR. Mol. Cancer Ther. 8, 3341\u20133349 (2009).","journal-title":"Mol. Cancer Ther."},{"key":"2843_CR436","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1182\/blood-2011-10-386789","volume":"120","author":"DJ Kuhn","year":"2012","unstructured":"Kuhn, D. J. et al. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood 120, 3260\u20133270 (2012).","journal-title":"Blood"},{"key":"2843_CR437","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.3390\/cancers12123568","volume":"12","author":"S de Groot","year":"2020","unstructured":"de Groot, S. et al. Unraveling the resistance of IGF-pathway inhibition in ewing sarcoma. Cancers 12, 3568 (2020).","journal-title":"Cancers"},{"key":"2843_CR438","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1179\/1973947815Y.0000000026","volume":"28","author":"X Zhou","year":"2016","unstructured":"Zhou, X. et al. PQ401, an IGF-1R inhibitor, induces apoptosis and inhibits growth, proliferation and migration of glioma cells. J. Chemother. 28, 44\u201349 (2016).","journal-title":"J. Chemother."},{"key":"2843_CR439","doi-asserted-by":"publisher","first-page":"5641","DOI":"10.3892\/mmr.2015.4129","volume":"12","author":"X Zhou","year":"2015","unstructured":"Zhou, X. et al. GSK1838705A, an IGF-1R inhibitor, inhibits glioma cell proliferation and suppresses tumor growth in vivo. Mol. Med Rep. 12, 5641\u20135646 (2015).","journal-title":"Mol. Med Rep."},{"key":"2843_CR440","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/neuonc\/nop008","volume":"12","author":"S Yin","year":"2010","unstructured":"Yin, S. et al. Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. Neuro Oncol. 12, 19\u201327 (2010).","journal-title":"Neuro Oncol."},{"key":"2843_CR441","first-page":"633","volume":"37","author":"DR Premkumar","year":"2010","unstructured":"Premkumar, D. R., Jane, E. P. & Pollack, I. F. Co-administration of NVP-AEW541 and dasatinib induces mitochondrial-mediated apoptosis through Bax activation in malignant human glioma cell lines. Int J. Oncol. 37, 633\u2013643 (2010).","journal-title":"Int J. Oncol."},{"key":"2843_CR442","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2147\/OTT.S80047","volume":"8","author":"Q Zhou","year":"2015","unstructured":"Zhou, Q. BMS-536924, an ATP-competitive IGF-1R\/IR inhibitor, decreases viability and migration of temozolomide-resistant glioma cells in vitro and suppresses tumor growth in vivo. Oncol. Targets Ther. 8, 689\u2013697 (2015).","journal-title":"Oncol. Targets Ther."},{"key":"2843_CR443","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1158\/1535-7163.MCT-14-0751","volume":"14","author":"N Wang","year":"2015","unstructured":"Wang, N. et al. The IGF-trap: novel inhibitor of carcinoma growth and metastasis. Mol. Cancer Ther. 14, 982\u2013993 (2015).","journal-title":"Mol. Cancer Ther."},{"key":"2843_CR444","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/neuonc\/noaf011","volume":"27","author":"YM Chen","year":"2025","unstructured":"Chen, Y. M. et al. Nanoparticle encapsulation enables systemic IGF-Trap delivery to inhibit intracerebral glioma growth. Neuro Oncol. 27, 1227\u20131240 (2025).","journal-title":"Neuro Oncol."},{"key":"2843_CR445","doi-asserted-by":"publisher","first-page":"4747","DOI":"10.1158\/1078-0432.CCR-14-0114","volume":"20","author":"P Haluska","year":"2014","unstructured":"Haluska, P. et al. Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors. Clin. Cancer Res. 20, 4747\u20134757 (2014).","journal-title":"Clin. Cancer Res."},{"key":"2843_CR446","doi-asserted-by":"publisher","first-page":"11329","DOI":"10.1074\/jbc.M611526200","volume":"282","author":"L Girnita","year":"2007","unstructured":"Girnita, L. et al. Beta-arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression. J. Biol. Chem. 282, 11329\u201311338 (2007).","journal-title":"J. Biol. Chem."},{"key":"2843_CR447","doi-asserted-by":"publisher","first-page":"7055","DOI":"10.1073\/pnas.1118359109","volume":"109","author":"H Zheng","year":"2012","unstructured":"Zheng, H. et al. Selective recruitment of G protein-coupled receptor kinases (GRKs) controls signaling of the insulin-like growth factor 1 receptor. Proc. Natl. Acad. Sci. USA 109, 7055\u20137060 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2843_CR448","doi-asserted-by":"publisher","first-page":"15688","DOI":"10.1074\/jbc.M010884200","volume":"276","author":"S Dalle","year":"2001","unstructured":"Dalle, S. et al. Insulin and insulin-like growth factor I receptors utilize different G protein signaling components. J. Biol. Chem. 276, 15688\u201315695 (2001).","journal-title":"J. Biol. Chem."},{"key":"2843_CR449","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1038\/onc.2010.640","volume":"30","author":"C Garofalo","year":"2011","unstructured":"Garofalo, C. et al. Efficacy of and resistance to anti-IGF-1R therapies in Ewing\u2019s sarcoma is dependent on insulin receptor signaling. Oncogene 30, 2730\u20132740 (2011).","journal-title":"Oncogene"},{"key":"2843_CR450","doi-asserted-by":"publisher","first-page":"20620","DOI":"10.1073\/pnas.1216348110","volume":"109","author":"H Zheng","year":"2012","unstructured":"Zheng, H. et al. \u03b2-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing\u2019s sarcoma. Proc. Natl. Acad. Sci. USA 109, 20620\u201320625 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2843_CR451","doi-asserted-by":"publisher","DOI":"10.1038\/srep06855","volume":"4","author":"T Zhang","year":"2014","unstructured":"Zhang, T. et al. Antitumor effects and molecular mechanisms of figitumumab, a humanized monoclonal antibody to IGF-1 receptor, in esophageal carcinoma. Sci. Rep. 4, 6855 (2014).","journal-title":"Sci. Rep."},{"key":"2843_CR452","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0300-9084(99)80088-1","volume":"81","author":"A Belfiore","year":"1999","unstructured":"Belfiore, A. et al. Insulin\/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer. Biochimie 81, 403\u2013407 (1999).","journal-title":"Biochimie"},{"key":"2843_CR453","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1530\/EC-13-0086","volume":"3","author":"D Weinstein","year":"2014","unstructured":"Weinstein, D., Sarfstein, R., Laron, Z. & Werner, H. Insulin receptor compensates for IGF1R inhibition and directly induces mitogenic activity in prostate cancer cells. Endocr. Connect 3, 24\u201335 (2014).","journal-title":"Endocr. Connect"},{"key":"2843_CR454","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200908","volume":"32","author":"S Khurshid","year":"2024","unstructured":"Khurshid, S. et al. Employing splice-switching oligonucleotides and AAVrh74.U7 snRNA to target insulin receptor splicing and cancer hallmarks in osteosarcoma. Mol. Ther. Oncol. 32, 200908 (2024).","journal-title":"Mol. Ther. Oncol."},{"key":"2843_CR455","first-page":"1935","volume":"5","author":"G Pandini","year":"1999","unstructured":"Pandini, G. et al. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin\/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin. Cancer Res. 5, 1935\u20131944 (1999).","journal-title":"Clin. Cancer Res."},{"key":"2843_CR456","doi-asserted-by":"publisher","first-page":"8770","DOI":"10.1158\/0008-5472.CAN-10-1093","volume":"70","author":"JC Potratz","year":"2010","unstructured":"Potratz, J. C. et al. Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas. Cancer Res. 70, 8770\u20138781 (2010).","journal-title":"Cancer Res."},{"key":"2843_CR457","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1128\/MCB.01868-05","volume":"26","author":"PA Kiely","year":"2006","unstructured":"Kiely, P. A. et al. Insulin-like growth factor I controls a mutually exclusive association of RACK1 with protein phosphatase 2A and beta1 integrin to promote cell migration. Mol. Cell Biol. 26, 4041\u20134051 (2006).","journal-title":"Mol. Cell Biol."},{"key":"2843_CR458","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1210\/me.2003-0143","volume":"17","author":"Y Ling","year":"2003","unstructured":"Ling, Y., Maile, L. A. & Clemmons, D. R. Tyrosine phosphorylation of the beta3-subunit of the alphaVbeta3 integrin is required for embrane association of the tyrosine phosphatase SHP-2 and its further recruitment to the insulin-like growth factor I receptor. Mol. Endocrinol. 17, 1824\u20131833 (2003).","journal-title":"Mol. Endocrinol."},{"key":"2843_CR459","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1091\/mbc.e03-04-0239","volume":"14","author":"LA Maile","year":"2003","unstructured":"Maile, L. A., Badley-Clarke, J. & Clemmons, D. R. The association between integrin-associated protein and SHPS-1 regulates insulin-like growth factor-I receptor signaling in vascular smooth muscle cells. Mol. Biol. Cell 14, 3519\u20133528 (2003).","journal-title":"Mol. Biol. Cell"},{"key":"2843_CR460","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00280-009-1083-9","volume":"65","author":"P Haluska","year":"2010","unstructured":"Haluska, P. et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother. Pharm. 65, 765\u2013773 (2010).","journal-title":"Cancer Chemother. Pharm."},{"key":"2843_CR461","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1210\/en.2012-2208","volume":"154","author":"DL Felice","year":"2013","unstructured":"Felice, D. L. et al. Growth hormone potentiates 17\u03b2-estradiol-dependent breast cancer cell proliferation independently of IGF-I receptor signaling. Endocrinology 154, 3219\u20133227 (2013).","journal-title":"Endocrinology"},{"key":"2843_CR462","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3390\/genes11070719","volume":"11","author":"N Fusco","year":"2020","unstructured":"Fusco, N. et al. PTEN alterations and their role in cancer management: are we making headway on precision medicine? Genes 11, 719 (2020).","journal-title":"Genes"},{"key":"2843_CR463","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41580-018-0015-0","volume":"19","author":"YR Lee","year":"2018","unstructured":"Lee, Y. R., Chen, M. & Pandolfi, P. P. The functions and regulation of the PTEN tumour suppressor: new modes and prospects. Nat. Rev. Mol. Cell Biol. 19, 547\u2013562 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2843_CR464","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1056\/NEJMra1704560","volume":"379","author":"MD Goncalves","year":"2018","unstructured":"Goncalves, M. D., Hopkins, B. D. & Cantley, L. C. Phosphatidylinositol 3-kinase, growth disorders, and cancer. N. Engl. J. Med. 379, 2052\u20132062 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2843_CR465","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O\u2019Reilly","year":"2006","unstructured":"O\u2019Reilly, K. E. et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500\u20131508 (2006).","journal-title":"Cancer Res."},{"key":"2843_CR466","doi-asserted-by":"publisher","first-page":"167","DOI":"10.4155\/tde-2021-0060","volume":"13","author":"M Tufail","year":"2022","unstructured":"Tufail, M. & Wu, C. Targeting the IGF-1R in prostate and colorectal cancer: reasons behind trial failure and future directions. Ther. Deliv. 13, 167\u2013186 (2022).","journal-title":"Ther. Deliv."},{"key":"2843_CR467","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1002\/ijc.32668","volume":"146","author":"DT Kruger","year":"2020","unstructured":"Kruger, D. T. et al. IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer. Int. J. Cancer 146, 2348\u20132359 (2020).","journal-title":"Int. J. Cancer"},{"key":"2843_CR468","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.ctrv.2014.07.004","volume":"40","author":"H King","year":"2014","unstructured":"King, H., Aleksic, T., Haluska, P. & Macaulay, V. M. Can we unlock the potential of IGF-1R inhibition in cancer therapy? Cancer Treat. Rev. 40, 1096\u20131105 (2014).","journal-title":"Cancer Treat. Rev."},{"key":"2843_CR469","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1158\/1535-7163.MCT-12-0447","volume":"11","author":"N Awasthi","year":"2012","unstructured":"Awasthi, N. et al. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor\/insulin receptor, enhances gemcitabine response in pancreatic cancer. Mol. Cancer Ther. 11, 2644\u20132653 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"2843_CR470","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nrclinonc.2011.121","volume":"8","author":"NB La Thangue","year":"2011","unstructured":"La Thangue, N. B. & Kerr, D. J. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat. Rev. Clin. Oncol. 8, 587\u2013596 (2011.","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02843-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02843-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02843-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:02:35Z","timestamp":1789081355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02843-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":470,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2843"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02843-w","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"30 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All the authors agree to the current state of the manuscript to be submitted to the journal.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"375"}}